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ABSTRACT  
The aim of this thesis was the development of new strategies for optical and 
optogenetic control of proliferative and pro-survival signaling, and characterizing 
them from the molecular mechanism up to cellular effects. These new light-based 
methods have unique features, such as red light as an activator, or the avoidance of 
gene delivery, which enable to overcome current limitations, such as light delivery to 
target tissues and feasibility as therapeutic approach. A special focus was placed on 
implementing these new light-based approaches in pancreatic β-cells, as β-cells are 
the key players in diabetes and especially their loss in number negatively affects 
disease progression. Currently no treatment options are available to compensate the 
lack of functional β-cells in diabetic patients.  
In a first approach, red-light-activated growth factor receptors, in particular receptor 
tyrosine kinases were engineered and characterized. Receptor activation with light 
allows spatio-temporal control compared to ligand-based activation, and especially 
red light exhibits deeper tissue penetration than other wavelengths of the visible 
spectrum. Red-light-activated receptor tyrosine kinases robustly activated major 
growth factor related signaling pathways with a high temporal resolution. Moreover, 
the remote activation of the proliferative MAPK/Erk pathway by red-light-activated 
receptor tyrosine kinases in a pancreatic β-cell line was also achieved, through one 
centimeter thick mouse tissue. Although red-light-activated receptor tyrosine kinases 
are particularly attractive for applications in animal models due to the deep tissue 
penetration of red light, a drawback, especially with regard to translation into 
humans, is the requirement of gene therapy.  
In a second approach an endogenous light-sensitive mechanism was identified and 
its potential to promote proliferative and pro-survival signals was explored, towards 
light-based tissue regeneration without the need for gene transfer. Blue-green light 
illumination was found to be sufficient for the activation of proliferation and survival 
promoting signaling pathways in primary pancreatic murine and human islets. 
Blue-green light also led to an increase in proliferation of primary islet cells, an effect 
which was shown to be mostly β-cell specific in human islets. Moreover, it was 
demonstrated that this approach of pancreatic β-cell expansion did not have any 
negative effect on the β-cell function, in particular on their insulin secretion capacity. 
In contrast, a trend for enhanced insulin secretion under high glucose conditions 
after illumination was detected. In order to unravel the detailed characteristics of this 
endogenous light-sensitive mechanism, the precise light requirements were 
determined. In addition, the expression of light sensing proteins, OPN3 and 
rhodopsin, was detected. The observed effects were found to be independent of 
handling effects such as temperature differences and cytochrome c oxidase 
dependent ATP increase, but they were found to be enhanced through the knockout 
of OPN3. The exact mechanism of how islets cells sense light and the identity of the 
photoreceptor remains unknown. 
Summarized two new light-based systems with unique features were established 
that enable the activation of proliferative and pro-survival signaling pathways. While 
red-light-activated receptor tyrosine kinases open a new avenue for optogenetics 
research, by allowing non-invasive control of signaling in vivo, the identified 
endogenous light-sensitive mechanism has the potential to be the basis of a gene 
therapy-free therapeutical approach for light-based β-cell expansion.  
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CHAPTER 1: LITERATURE REVIEW  
1.1 Photoreceptors 
1.1.1 Photoreceptor introduction  
The ability to sense light is widespread among prokaryotes and eukaryotes. Light is 
a major stimulus that initiates a signal upon absorption of a photon, transmits this 
signal through complex molecular and metabolic pathways, and ultimately results in 
modified behavior.1 In microbes and plants, light modifies biological activities such as 
light-induced movements and phototropism, whereas in mammalians, light mediates 
vision and the regulation of the circadian rhythm.2,3 Light is directly absorbed by 
protein molecules known as photoreceptors.3 Photoreceptors have evolved in 
diverse biological systems to sense light, and their absorption spectrum ranges over 
specific regions of the electromagnetic spectrum, covering the ultraviolet, visible and 
near-infrared region (Figure 1.1).3 Because the polypeptide backbone and amino 
acid side chains of photoreceptors do not absorb light in this range, almost all 
photoreceptors need a prosthetic light-absorbing cofactor, known as a chromophore, 
to be functional. Chromophores act as the primary photon acceptor and can be 
covalently or non-covalently bound to the photoreceptor. The corresponding 
chromophore of each photoreceptor is responsible for its specific absorption 
spectrum (Figure 1.1).3 In response to photon absorption, photoreceptors undergo 
different structural rearrangements, including the opening of transmembrane ion 
channels, the unfolding of terminal secondary structure motifs as well as the 
formation or disruption of protein-protein interactions, such as hetero- and 
homodimerization or oligomerization.4,5 Photoreceptors are commonly classified into 
six different classes by their chemical nature and the photochemistry of their 
chromophore: ultraviolet-B (UV-B) light photoreceptors, flavin-binding 
photoreceptors, xanthopsins, adenosylcobalamine-binding photoreceptors, 
phytochromes and opsins.3,5,6  
2 
 
 
 
Figure 1.1 Absorption spectra of different chromophores. The specific chromophore of 
each photoreceptor is responsible for its specific absorption spectrum. Chromophores of 
main photoreceptor classes: (1) tryptophan, (2) p-coumaric acid, (3) flavin, (4) retinal, (5) 
tetrapyrroles, (6) adenosylcobalamine. 
1.1.2 UV-B light photoreceptors 
UV-B light is a key environmental signal that is specifically recognized by plants to 
promote UV adaption and survival in sunlight. Although UV-B (280–315 nm) 
represents less than 0.5% of total sunlight energy reaching the earth’s surface, it 
causes photomorphogenic responses in plants that modify their biochemical 
composition, photosynthetic competence and morphogenesis.5,7 UV-B is absorbed 
by the UVR8 photoreceptor, which is a β-propeller protein originally identified in 
Arabidopsis thaliana.5 The UVR8 protein is localized in the cytoplasm and the 
nucleus, but upon UV-B irradiation it accumulates in the nucleus, where it interacts 
with the E3 ubiquitin ligase, constitutive photomorphogenic 1 (COP1), which is a 
central regulator of UV-B and visible light responses.5,8 This UV-B-dependent 
nuclear localization of the receptor is necessary for its activation.5 In its inactive 
state, UVR8 is present as a homodimer, whereas absorption of UV-B light leads to 
the dissociation of UVR8 dimers into monomers within seconds.5 UV-B-dependent 
monomerisation of the Arabidopsis thaliana UVR8 homodimers is independent of the 
host cell and can be reproduced in yeast or human cells, by expressing the UVR8 
receptors in these cells.9 The structural change from a dimer to monomer requires a 
chromophore, which perceives UV-B irradiation and initiates the photoreceptor 
mediated signal transduction.5 UVR8 is a noteworthy photoreceptor, because in 
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contrast to other known photoreceptors that use a prosthetic cofactor, UVR8 uses 
specific tryptophan amino acids as a chromophore for UV-B light absorption.5,7 The 
investigations of the physiological role of UVR8 are still at an early stage. Initial 
studies focused on gene regulation by UVR8 and demonstrated its importance in UV 
protection.7 There is solid evidence that UVR8 and COP1 act together to mediate 
photomorphogenic UV-B responses by promoting the expression of the basic 
leucine-zipper transcription factor elongated hypocotyl 5, which is one of the most 
important promoters of photomorphogenesis.5,7 Nevertheless all discoveries are 
derived from studies with Arabidopsis thaliana. Therefore, much remains to be 
studied about the physiological role of UVR8 in other, diverse species.7 
1.1.3 Flavin-binding photoreceptors 
Blue light (300–500 nm) in particular acts to promote a wide variety of 
photomorphogenic responses in plants, including seedling establishment, 
phototropism and circadian clock regulation.10 Flavin-binding photoreceptors sense 
blue light through a riboflavin derivative cofactor, and are further subdivided into 
cryptochromes (CRYs), proteins containing light-oxygen-voltage (LOV) domains, and 
blue light sensors using flavin adenine dinucleotide (BLUF).10,11 Genetic analyses in 
the model plant Arabidopsis thaliana have been used to identify the molecular basis 
of blue light receptors and their mechanism of action.10 In general, the 
photoexcitation of the flavin cofactor leads to changes in redox and protonation 
states that ultimately modify the protein conformation and its molecular 
interactions.11 
1.1.3.1 CRYs 
CRYs were the first plant blue light receptors to be characterized at the molecular 
level. Although they were first identified in Arabidopsis thaliana, they are present 
throughout the biological kingdom, from archaebacteria to mammals.10,12 CRYs are 
key components of various light-dependent responses such as photoperiodic control 
of flowering in plants and entrainment of the circadian clock in plants and 
animals.3,11,12 CRYs exhibit significant homology to the photolyase (PL) family of 
proteins, which are blue-light-activated enzymes found in both prokaryotes and 
eukaryotes that catalyze light-dependent repair of damaged DNA following exposure 
to UV-B irradiation.10,11,13 CRYs bind two different chromophores at their N-terminal 
chromophore binding domain, flavin adenine dinucleotide (FAD) and 
methenyltetrahydrofolate (MTHF). FAD is bound non-covalently within the PL 
homology region (PHR) and functions as the primary light sensor, whereas MTHF 
serves as an antenna cofactor to harvest and transfer additional light energy to the 
FAD chromophore from the near UV region (370–390 nm).10 The N-terminal 
chromophore binding domain is highly conserved among all classes of CRYs and 
PLs, whereas the C-terminal domains (CCTs), which are the effector domains and 
important for CRY signaling, are of variable length and poorly conserved, even 
among CRYs of the same species. In animals, CRYs are divided into two subtypes 
based on their responsiveness to light: Type I CRYs act as circadian photoreceptors 
(as in Drosophila), whereas Type II CRYs exert their function without responding to 
light (as in mouse, human, and other vertebrates). Some vertebrates, such as 
zebrafish have both types of CRYs.12 In Arabidopsis thaliana, three CRYs have been 
identified, which are also the best characterized ones to date: CRY1, CRY2 and 
CRY3. CRY1 and CRY2 exhibit no DNA repair activity but instead, upon blue light 
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absorption, directly or indirectly regulate transcription by interacting with other 
proteins, such as the basic helix-loop-helix transcription factor calcium and integrin-
binding protein 1 (CIB1) and COP1 to control various processes, such as plant 
growth or flowering. CRY2 undergoes blue-light-dependent ubiquitination and 
degradation in the nucleus and functions preferentially under low light conditions.10 In 
contrast, CRY3 localizes to mitochondria and chloroplasts to repair UV-induced 
lesions in single-stranded DNA and in loop structures of double-stranded DNA.10,14,15 
In all CRYs, the PHR domain and the CCT are proposed to form a closed or inactive 
conformation in the dark, while blue light absorption by the PHR domain triggers a 
conformational change in the CCT to produce an open or active conformation that 
initiates signaling.10 Upon photoexcitation, it is generally agreed that a series of 
biophysical and biochemical changes mediated by FAD lead to structural 
rearrangement, protein modification (phosphorylation) and interaction with signaling 
proteins including (e.g. CIB1 and COP1) (Figure 1.3 C).16 However, the mechanism 
by which the FAD to FADH● transition within the PHR domain is propagated to 
induce the proposed conformational change within the CCT is still not fully 
understood.10 Based on the different absorption spectra it is argued that the oxidized 
from of FAD, which strongly absorbs blue light (λmax ≈ 450 nm), is most likely present 
in the dark and inactive state of the photoreceptor. Irradiation of the PHR domain 
results in a sequential electron transfer from three tryptophan residues to reduce 
FAD to FADH●.17 However, while extensive structural, spectroscopic, biochemical, 
and computational studies have been brought to bear on the associated light-
sensing mechanisms, many of the resolved features and their implications remain 
controversial. 
1.1.3.2 LOV 
LOV domains were first identified in the plant photoreceptor phototropin, but LOV 
domains have since been discovered in several plant, fungi, archaea and bacterial 
proteins, such as the fungal light-adaptation protein Vivid, and YtvA, a LOV protein 
from B. subtilis involved in stress responses.3,11 LOV domains are a subset of the 
PER-ARNT-SIM (PAS) domain superfamily that uses a non-covalently bound flavin 
cofactor, flavin mononucleotide (FMN) or FAD that absorbs UVA and blue light.11,18 
Upon light absorption, a covalent bond between the cofactor and a conserved 
cysteine residue is formed.11 This leads to conformational changes which, in plant 
phototropins, induce the C-terminal α-helix (Jα) to undock from the LOV core and 
unfold, consequently inducing downstream effector functions (Figure 1.3 B). In other 
LOV proteins, activation can induce dimerization or rotation of LOV domain subunits 
(Figure 1.3 A).19 The induced signaling mechanisms depend on various factors such 
as the oligomeric state, the flanking helical content, and the character of the effector 
domain.11 Usually, the photoreaction is fully reversible and the signaling state 
thermally reverts to the ground, dark state. However, despite similar sequence and 
structure, individual LOV domains differ distinctly in the kinetics and quantum yield of 
their photocycle. The basis for these differences may be linked to protein flexibility or 
to solvent accessibility, or the specific environment of the flavin chromophore in the 
protein core, where mutations can strongly affect photocycle kinetics.3 Although the 
photochemistry of the LOV flavin is relatively well defined, some key issues remain 
unresolved. These include the identity of intermediates preceding adduct formation, 
proton transfer during the reaction, and in particular, factors influencing the highly 
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variable dark-state recovery rates, where timescales vary between seconds to 
hours.11,18  
1.1.3.3 BLUF 
BLUF domains are a family of photosensor domains that use FAD to detect blue 
light. They predominantly occur in prokaryotes and they were first identified and are 
most extensively studied in activation of photopigment and puc expression A (AppA) 
from Rhodobacter sphaeroides, where they regulate photosynthetic gene 
expression. BLUF domains are also found in eukaryotes, such as euglenozoa and 
fungi.3 They exist either as isolated domains or covalently linked to effector domains, 
which are mostly involved in cyclic nucleotide metabolism.3,20 BLUF domains are 
oligomeric and have a ferredoxin-like module with two helices aligned in parallel to a 
five-stranded mixed parallel/antiparallel β-sheet.11 The FAD chromophore is 
embedded in a cleft between two α helices.3,11 In contrast to LOV domains, the FAD 
cofactor of BLUF domains undergoes minimal conformational changes upon blue 
light absorption, and the signaling state is rapidly formed on the sub-nanosecond 
timescale. Light absorption at the ground state leads to an electron transfer from a 
conserved tyrosine residue to the flavin ring and gives rise to a short-lived radical 
pair. The side chain of a nearby, conserved glutamine residue is assumed to rotate, 
which is followed by a back transfer of an electron to the tyrosine to form the 
signaling state.3 Upon conversion from the dark, inactive to the light-adapted, active 
state, the flavin absorption spectra of BLUF domains undergo a ~10 nm redshift 
which can persist from seconds up to minutes. This red-shifted spectrum results from 
the modulation of hydrogen bonds among the flavin and a tyrosine-glutamine-
methionine-tryptophan tetrad.11 It is known that in both the inactive and the signaling 
states, FAD maintains its fully oxidized state, but further details of the BLUF 
photocycle are still under debate.3  
1.1.4 Xanthopsin 
The xanthopsin photoreceptor class is represented by the photoactive yellow protein 
(PYP), which is a small, water-soluble, cytoplasmic photoreceptor of 126 amino 
acids that, upon absorption of blue light, undergoes a fully reversible photocycle that 
contains several intermediates.3,21 PYP was first found in the extremely halophilic 
purple photosynthetic bacterium Halorhodospira halophile.21,22 Although the protein 
has only been isolated from few sources, genomic and metagenomic analyses have 
identified more than 140 PYP genes that occur in a wide variety of bacteria and 
different metabolic niches.21 In Halorhodospira halophile, PYP has been proposed to 
be involved in negative phototaxis triggered by blue light, while in Rhodobacter it is 
thought to be involved in the regulation of cell buoyancy. PYP serves as the 
structural paradigm for the PAS domain family of proteins, which is a key element in 
biological signal transfer also shared by LOV domains.3 PYP uses a 
p-4-hydroxycinnamic acid (p-coumaric acid) as chromophore, which undergoes a 
trans-to-cis isomerization upon blue light illumination. In the dark state, the 
chromophore is stabilized by a thioester bond to a cysteine residue and by 
abnormally short hydrogen bonds to nearby glutamic acid and tyrosine side chains.3 
The blue-light-induced trans-to-cis isomerization of the p-coumaric acid is followed 
by several structurally distinct intermediates. The complete isomerization occurs 
within a few nanoseconds and introduces severe strain into the chromophore and 
the surrounding protein.3 The relaxation of this strain initiates a long series of 
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changes in tertiary structure, such as rupture of a hydrogen bonds, ejection of the 
chromophore toward the solvent, partial unfolding of the Cα helix, and, ultimately, 
unfolding of N-terminal α helices packed on the distal side of the β sheet, which 
forms the structural core of all PAS and LOV domains including PYP.3 By means of 
time-resolved crystallographic studies, high-resolution structures of PYP photocycle 
intermediates were obtained covering time scales from nano- to femtoseconds.23,24 
1.1.5 Adenosylcobalamin-binding photoreceptors  
Adenosylcobalamin-binding photoreceptors are a new class of photoreceptors that 
have only been recently characterized. These photoreceptors are members of the 
LitR/CarH family and sense ultraviolet, blue and green light using the vitamin B12 
derivate adenosylcobalamine (AdoCbl) as a chromophore.6,25 AdoCbl was originally 
identified as a cofactor for radical-based enzyme reactions, and only recently its 
biological function could be expanded to light sensing.26 The LitR/CarH 
photoreceptors contain a C-terminal cobalamin-binding domain and are involved in 
light-induced transcriptional regulation.25 Homologs of LitR/CarH exist widely in non-
phototrophic bacteria and the best characterized photoreceptors are from 
Myxococcus xanthus (MxCarH) and Thermus thermophilus (TtCarH).25-28 In these 
organisms, CarH controls the light-induced expression of carotenoids, which mediate 
protection against photo-oxidative damage.26-28 In the dark, CarH-type 
photoreceptors form dimer-of-dimers type tetramers.6,26 Each monomer of CarH 
consists of an N-terminal DNA binding domain and a C-terminal AdoCbl-binding and 
oligomerization domain that is responsible for light-sensing.26 The flexible DNA-
binding domain displays a canonical recognition helix and β-hairpin wing for DNA 
binding. The light-sensing, AdoCbl-binding domain is composed of a four-helix 
bundle and a Rossman-fold domain and is structurally rigid. In the tetramer, the four 
light-sensing domains together form a central core and the DNA-binding domains are 
displayed on the surface.26 In the dark, the AdoCbl-bound CarH tetramer binds to the 
promoter region of target genes, such as the carotenoid synthesis operon, to block 
transcription.6,26 Illumination with ultraviolet, blue, or green light causes photolysis of 
the cofactor, through rupture of the photosensitive Co-C bond in AdoCbl, resulting in 
rearranging of the four-helix bundle and subsequent tetramer disassembly (Figure 
1.3 E). This consequently leads to loss of operator-binding and the activation of gene 
expression.26 
1.1.6 Phytochromes 
Phytochromes make up the diverse family of red/far-red responsive photoreceptors 
first discovered in plants, where they are one of the three major regulators of 
photomorphogenesis3,29, but they are also found in the microbes such as 
cyanobacteria, proteobacteria and filamentous fungi.30,31 In the last two decades a 
variety of new bacterial and cyanobacterial members of the phytochrome family have 
been identified, which has greatly facilitated the biochemical and structural 
characterization of this family.29 All phytochromes are photoswitchable photosensors 
that utilize a covalently attached linear tetrapyrrole, a bilin chromophore, to 
photoconvert between a red-light-absorbing (Pr) biologically inactive state and 
far-red-light-absorbing (Pfr) biologically active state. Although dark reversion is an 
intrinsic property of all phytochromes, plant phytochromes have evolved a slower 
dark reversion. Plant phytochromes, bacteriophytochromes and cyanobacterial 
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phytochromes share a similar domain architecture and high sequence homology. 
They are homodimeric complexes that consist of an N-terminal photosensory region 
with 3 conserved domains, PAS, cGMP-specific phosphodiesterase adenylate 
cyclase FhlA (GAF) and phytochrome-specific GAF-related domain (PHY), and a C-
terminal regulatory histidine kinase or histidine kinase-related domain.3,29,30 The two 
N-terminal domains, PAS and GAF, together form a chromophore binding domain.3 
The full photocycle involves absorption of two photons, one to drive the forward 
transition (Pr to Pfr), and the other for the backward transition (Pfr to Pr).32 All four 
pyrrole nitrogens in the bilin chromophore are protonated in both the Pr and Pfr 
states,3 where the primary photochemical transition involves the isomerization of the 
bilin chromophore. In the traditional view, this cis-to-trans isomerization occurs 
around the C15 and C16 double bond between rings C and D in the prosthetic bilin 
chromophore, consequently leading to a flip of the D ring. However, recent studies 
suggest that in certain phytochromes isomerization occurs due to the linkage 
between the A and B rings.32 The combined structural data on microbial 
phytochromes support a largely unifying post-isomerization mechanism for 
photoreceptor action. This mechanism involves the reorientation of the PHY domain 
relative to the GAF domain by altering the PHY hairpin contact, and motion within the 
GAF domain, resulting in an effect on the dimerization contact along the entire 
interface of the phytochrome dimer. Finally, the relative positions of the output 
modules are rearranged. While variations in the bilin photochemistry have been 
identified among various phytochrome types, many important key residues and 
structural motifs of the phytochrome assembly and photochemistry seem to be highly 
conserved, suggesting that most members of the phytochrome family employ a 
similar conformational signaling mechanism.31 In plants, absorption of red light by the 
Pr form, which results in a transition to the Pfr form, subsequently leads to the 
recruitment of downstream signaling molecules such as phytochrome interacting 
factors (PIF) (Figure 1.3 C).19 
1.1.7 Opsins 
In contrast to the other five soluble photoreceptor classes, opsins are membrane 
proteins.3,4 They are photoreceptors that serve as the primary light-sensitive proteins 
in vision and also in the entrainment of circadian rhythms in mammals, but related 
proteins, in particular rhodopsins, have also been identified as photoreceptors in 
microorganisms and algae.3,33 Plant as well as bacterial rhodopsins belong to the 
large family of seven-helix transmembrane proteins. Light is sensed via a retinal 
chromophore that is covalently bound to a lysine residue as a protonated Schiff 
base. In plant and bacterial rhodopsin, the dark-adapted state binds a retinal 
chromophore in the all-trans conformation. Upon blue-light absorption around 470 
nm, the retinal isomerizes to the 13-cis form, which initiates a cycle of structural 
changes.3,4 A well-known example of plant rhodopsins is channelrhodopsin, which 
mediates phototaxis in flagellate algae, and was first identified in Chlamydomonas 
reinhardtii as light-gated cation channel.34 Other algal rhodopsins function as light 
driven H+ pumps similar to bacteriorhodopsin, although their physiological role in 
photosynthetic organisms remains unclear.3 Microbial rhodopsins mediating light-
driven ion transport fall into two categories: actively transporting ion pumps and ion 
channels.4  
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In higher species, opsins are the light-sensitive proteins found in photoreceptor cells, 
but are also present in non-visual tissue. Like in microorganisms and plants, 
mammalian opsins are seven-transmembrane receptors which use retinal as a 
chromophore. In contrast to microbial rhodopsin, mammalian opsins preferentially 
bind 11-cis retinal as a chromophore in the dark instead of all-trans retinal. Upon 
light absorption by the opsin-chromophore complex, retinal isomerizes to the 
all-trans form. Retinal isomerization in turn causes conformational changes in the 
opsin, which allow coupling to distinct G-proteins and further activation of 
downstream signalling pathways.33 Generally, mammalian opsins are divided into 
visual and non-visual opsins, with distinct functions and G-protein coupling 
specificity.33,35 
1.1.7.1 Visual mammalian opsins 
Visual opsins are found in the photoreceptor cells of the retina. Cone cells express 
cone opsins and are responsible for color vision, while rod cells express rhodopsin 
which regulates twilight vision. Humans have one rhodopsin, and three cone opsins: 
short-, medium-, and long-wave-sensitive opsin (OPN1SW, OPN1MW and 
OPN1LW, respectively). Mice, on the other hand, lack the red-light-sensing 
OPN1LW.36 Vertebrate rod and cone opsins are bleaching photopigments, which 
means that the photoproduct of the opsins is unstable and dissociates from its 
activated chromophore.35 Upon chromophore activation visual opsins couple to the 
heterotrimeric G-protein transducin (Gt) which consists of three polypeptide chains: 
Gα, Gβ and Gγ. The Gα subunit of Gt couples to phosphodiesterase 6 (PDE6), an 
enzyme that hydrolyses cyclic guanosine monophosphate (cGMP). Decreased levels 
of cGMP cause the closure of cyclic nucleotide gated channels (CNG channels), 
which in turn leads to the hyperpolarization of the cell (Figure 1.2).35,37  
1.1.7.2 Non-visual mammalian opsins 
In contrast to visual opsins, the function of non-visual opsins in general is less 
explored. They are thought to be involved in physiological mechanisms such as 
circadian rhythm, temperature regulation, pupillary constriction as well as body 
pigmentation.35 However, the exact function depends on the opsin and for some, the 
function is still unclear.  
Melanopsin, also called opsin 4 (OPN4), is the most studied and best understood of 
the non-visual mammalian opsins. Its expression is mainly restricted to a 3rd class of 
photoreceptor cells next to rods and cones, a small subset of intrinsically 
photosensitive retinal ganglion cells. Melanopsin was found to be involved in 
pupillary constriction, the regulation of sleep and circadian photoentrainment.38 It is 
maximally sensitive to blue light (Table 1.1).39 Human melanopsin couples to Gαq 
and Gαi, whereas the coupling to Gαq seems much more efficient than to Gαi. Gαq 
coupling of melanopsin leads to the activation phospholipase C (PLC). PLC in turn, 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to diacyl glycerol (DAG) and 
inositol trisphosphate (IP3) , which results in an increase of the intracellular calcium 
concentration and consequently leads to cell depolarization (Figure1.2).39,40  
Opsin 3 (OPN3) was initially called encephalopsin because it was first found in the 
brain41, but was later renamed panopsin as it was found to be expressed in a wide 
range of tissues including brain, liver, and retina.42 The function of OPN3 is still 
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unclear, even though there is some evidence that OPN3 can be linked to asthma 
susceptibility, pigmentation and pulmonary vasorelaxation.43-45 The spectral 
properties of vertebrate (pufferfish) and invertebrate (mosquito) OPN3 homologs 
were identified, which both have an absorption maximum in the blue to green region 
(Table 1.1). Both OPN3 variants showed a bistable nature, which means that after 
cis-retinal isomerization, the pigment can photoisomerize all-trans retinal back to 
cis-retinal upon light stimulation. In the same study, it was found that OPN3 
homologs couple to the Gαi signaling cascade, which consequently leads to an 
inhibition of adenylate cyclase activity and thus a decrease of the intracellular cAMP 
concentration (Figure 1.2).46 Mammalian OPN3 could not be characterized to date. 
Opsin 5 (OPN5) also known as neuropsin is the most recently identified mammalian 
opsin.47 Human and mouse OPN5 exhibit an absorption maximum at 380 nm and 
they also display a bistable nature (Table 1.1). Upon UV light illumination, OPN5 is 
converted to a blue-absorbing state, with an absorption maximum of 470 nm, and 
activates the Gαi signaling cascade (Figure 1.2).48,49 Recently it could be shown that 
OPN5 is involved in the mediation of photoentrainment of local circadian oscillators 
in mammalian retina and cornea.50 
 
 
Figure 1.2 Opsin signaling via heterotrimeric G-proteins. Visual and non-visual opsins 
signal through different G-proteins. Visual opsins couple to the Gt pathway, which leads to a 
decrease in cGMP and closure of CNG channels. Melanopsin couples to Gαq, which raises 
IP3 and DAG levels resulting in increased intracellular calcium concentration. OPN3 and 
OPN5 couple to Gαi, which decreases cAMP levels.  
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Table 1.1 Spectral properties and photochemical characteristics of mammalian visual 
and non-visual opsins. Opsins can be classified into visual and non-visual opsins, with 
different absorbance maxima as well as different photopigment characteristics for each 
opsin. Absorbance is also species specific.  
Name Absorbance 
λ max [nm] 
Photopigment 
Characteristics 
References 
Visual Opsins 
Rhodopsin 500 Bleaching Imai et al. 200651 
OPN1SW 
(blue cone opsin) 
358 (mouse) 
420 (human) Bleaching 
Fasick et al. 200252 
Deeb et al. 2005 53 
OPN1MW 
(green cone opsin) 
508 (mouse) 
530 (human) Bleaching 
Sun et al. 199754 
Deeb et al. 200553 
OPN1LW 
(red cone opsin) 
560 (human) Bleaching Deeb et al. 2005 53 
Non-visual Opsins 
Melanopsin 
500 (mouse) 
479 (human) 
Bistable 
Walker et al. 200855 
Bailes et al. 201339 
OPN3 460/ 470 (pufferfish) Bistable Koyanagi et al. 2013 46 
OPN5 
380/470 (mouse and 
human) 
Bistable Kojima et al. 201148 
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1.2 Optogenetic tools  
Naturally-occurring photoreceptors and their light-sensing domains have been 
harnessed in recent years in the emerging field of optogenetics.1,56-59 The 
development of optogenetics was motivated by the observation that light can be an 
ideal stimulus to control cell and animal behavior, as it can be applied and withdrawn 
remotely and therefore permits transient and local activation on very short time and 
length scales (e.g. milliseconds and micrometers).1,60 Optogenetics flourished in the 
hands of neurobiologists that utilized microbial opsins to dissect neural circuits,1,56 
but more recently optogenetic approaches also started to have a big impact on cell 
biology, by regulating important cellular signaling pathways such as mitogen-
activated protein kinases/extracellular signal-regulated kinase (MAPK/Erk) pathway 
and cell behaviors (e.g. cell fate) by light.61 General advantages of optogenetics over 
pharmacology and genetics include the ease with which light can be applied and 
withdrawn and the possibility of transient and local light activation.60  
However, a persisting challenge in cell signaling optogenetics is to couple 
photoreceptors or their domains to protein targets, resulting in functional chimeras. 
Success in tackling this challenge depends on two factors, first a profound 
understanding of the biochemical, biophysical and structural photoreceptor 
properties, and second the expansion of the photoreceptor repertoire.62 By now there 
is a relatively broad spectrum of optogenetic tools available that use different 
photoreceptors or photoreceptor domains as a light sensing module to induce 
various cell behavioral outputs. In particular, CRY, LOV domains and phytochromes 
are frequently used as light sensing modules.19 For example, the LOV2 domain from 
Avena sativa phototropin 1 was used to control actin-based contractility and 
directional cell movement in mammalian cells. In this setup, the LOV2 domain was 
fused to the N-terminus of the GTPase ras-related C3 botulinum toxin substrate 1 
(Rac1), thereby sterically blocking the binding of Rac1 effectors. Upon blue light 
illumination the unfolding of Jα releases (Figure 1.3 B) the inhibition and induce 
Rac1-dependent actin assembly.63 A second LOV domain based approach mimicked 
growth factor based mitogenic and morphogenic cell behavior by light-activated 
receptor tyrosine kinases (RTKs). This was achieved by fusing LOV domains from 
the Vaucheria frigida aureochrome photoreceptor to the C-terminus of RTKs, which 
led to blue-light-dependent receptor dimerization and activation (Figure 1.3 A).64 
Recently also a green-light-based RTK inactivation system was engineered by using 
the CarH domain.65 An example for CRY based systems are tools where light-
inducible heterodimeric interaction of CRY2 and CIB1 (Figure 1.3 C) from 
Arabidopsis thaliana was used to induce protein translocation, transcription, and 
Cre-mediated DNA recombination by light,66 as well as a CRY2 based approach that 
allows light-induced, rapid, robust, and reversible protein oligomerization (Figure 1.3 
D).67 While blue-light-activated LOV domain- and CRY2-based systems return to 
their inactive state only by slow spontaneous decay in the dark, a major advantage 
of phytochrome-based red/far-red light-responsive systems is the possibility to 
actively switch between two states by illumination with either red or far-red light. 
Moreover, red light exhibits a much deeper tissue penetration compared to blue light, 
which is advantageous for in vivo applications. The natural chromophore of 
phytochromes, phytochromobilin, is not available in orthologous systems, but a 
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related tetrapyrrole, phycocyanobilin, is commercially available or can be easily 
extracted from the cyanobacterium Spirulina, and can be added to the culture media 
to substitute for the natural chromophore.19 For example, a heterodimeric 
phytochrome system was used for regulating gene expression in mammalian cells 
(Figure 1.3 C). This was achieved by splitting a transcription factor consisting of the 
tetracycline repressor TetR fused to PIF6 and a nuclear-targeted phytochorme B 
fused to the VP16 transactivation domain. Red light illumination induced reversible 
reconstitution of the transcription factor, triggering reporter expression from a 
response construct that contained a TetR-specific operator upstream of a minimal 
promoter.68 
 
 
Figure 1.3 Light-induced structural changes of different photoreceptors. (A) 
Blue-light-induced homodimerization occurs for example in LOV domains, which were used 
for light-induced RTK activation. (B) Blue light illumination of some LOV domains leads to 
the unfolding of the C-terminal Jα helix. This mechanism can be used by fusing proteins to 
the Jα helix and thereby sterically inhibiting them in the dark and releasing them during 
illumination. (C) Light-induced heterodimerization of light-sensing domains with for example 
different transcription factors such as CIB or PIF occurs in blue-light-absorbing CRYs as well 
as in red-light-absorbing phytochrome domains. This mechanism was also already used in 
several optogenetic tools. (D) Blue-light-induced oligomerization occurs in blue-light-sensing 
CRY domains. (E) Green light-induced dissociation of CarH-type photoreceptors was 
already used for light-controlled inactivation of RTKs.  
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1.3 β-cells 
1.3.1 Pancreas  
The pancreas is an organ, which is essential for keeping the nutritional household in 
balance and it is critically involved in the regulation of glucose homeostasis.69 The 
architecture of the rodent pancreas is often less defined in shape compared to the 
human pancreas, where designated regions are termed head, neck, body and tail. 
Also birds, reptiles and amphibians have a pancreas with a similar histological 
anatomy and developmental program as mammals.70 The pancreas comprises two 
distinct tissue types, the exocrine tissue and the endocrine tissue. These two tissues 
have entirely different functions as well as distinct morphologies.71 The exocrine cells 
secrete enzymes into the digestive tract, while the endocrine cells secrete hormones 
into the bloodstream to tightly regulate the circulating glucose levels.70 The 
endocrine tissue represents ~2% of the pancreas and it is made up of cell clusters of 
endocrine cells called the “islets of Langerhans”.69 Each islet in turn is composed of 
five different types of cells, namely, insulin-producing β-cells, glucagon-releasing α-
cells, somatostatin-producing δ-cells, pancreatic polypeptide-containing PP cells, 
and ghrelin-containing ε-cells. Together these cells are involved in the tight 
regulation of circulating glucose levels.69 The exocrine portion is composed of ductal 
cells and acinar cells.71 These form a branched, acinar gland with its secretory cells 
grouped into acini. They are secreting up to 22 different inactive precursor enzymes, 
including proteases, amylases, lipases and nucleases, which become active after 
they enter the duodenum.70 Each of these disparate pancreatic cell types derive from 
the same endodermal origin of the upper duodenal region of the foregut, which later 
gives rise to the digestive system. The development of the pancreas starts with a 
dorsal and ventral protrusion of a region of the primitive gut epithelium, which later 
converges to form the pancreas.70,72 Endocrine cells are the first to develop and 
differentiate, whereas exocrine and ductal cells develop from the same progenitors, 
but at a later stage. Another interesting aspect of the endocrine cell development is 
the remarkable similarity to neuronal cells regarding their expression of hormones 
and enzymes during their differentiation.72 
1.3.1.1 Islets of Langerhans 
Islets of Langerhans are highly vascularized micro-organs located in the pancreas. 
As described in the previous section, islets consist of a diverse cluster of endocrine 
cells that function together to control glucose homeostasis.73 The size of rodent and 
human islets can vary, from a few cells up to thousands of cells and a diameter of 
~50 µm up to ~500 µm.73,74 In rodent islets, there is a clear segregation of cell types 
to different islets regions. β-cells are clustered in the central islet core and smaller 
numbers of α-cells, δ-cells, PP cells and ε-cells are located in the periphery 
surrounding the β-cells (Figure 1.4 A). In contrast, human islets have a more random 
organization of endocrine cells (Figure 1.4 B).73,75 Another pancreatic islet property 
that displays species variability is the proportion of the different cell types. Murine 
islets are composed out of 70–80% β-cells and of a smaller portion of α-cells 
(~15%), δ-cells (less than 10%) and PP cells (less than 1%), whereas human islets 
contain only around 50% β-cells but much larger portions of α-cells (~40%) as well 
as δ-cells (~ 10%) and PP cells (less than 5%).73,75  
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Figure 1.4 Comparison of architectural organization of (A) rodent and (B) human 
islets. Spatial distribution of β-cells (green), α-cells (red), and δ-cells (blue) are illustrated 
based on immunohistochemical images. (Modified image from Steiner et al. 2010)73,75 
1.3.1.2 Maintenance of glucose homeostasis 
Glucose is an important source of energy for many organs and tissues in the body. 
Especially the brain derives its metabolic energy almost exclusively from glucose. 
Glucose is also an important regulatory signal that controls the secretion of 
hormones by various endocrine cells.76 The endocrine pancreas is the key actor in 
blood glucose homeostasis. β-cells in particular play a major role in the regulation of 
blood glucose levels, by functioning as glucose sensors as well as 
glucose-dependent insulin releasers.77 Insulin is a 51 amino acids long protein 
polypeptide, composed of an A and a B chain, which are linked by disulfide bonds. 
Insulin is synthesized as proinsulin by ribosomes of the rough endoplasmic reticulum 
(RER). Secretory vesicles transport the proinsulin from the RER to the Golgi 
apparatus, where proinsulin forms hexamers. Enzymes acting outside of the Golgi 
finally convert proinsulin to insulin and C-peptide, which are secreted into the 
circulation by exocytosis.78 The first step of glucose metabolism (Figure 1.5) is the 
uptake of glucose through the β-cell membrane by the low affinity glucose 
transporter-2 (GLUT-2).77 After glucose has entered the β-cell, it is further processed 
by glucokinase (GK). GK belongs to the family of hexokinases and catalyzes the 
phosphorylation of glucose to glucose-6-phosphate (G6P), thus trapping glucose 
inside the cell. G6P is then further processed by glycolysis and finally enters the 
citric acid cycle, which consequently leads to an increase in adenosine triphosphate 
(ATP) to adenosine diphosphate (ADP) ratio, and the initiation of the first phase of 
insulin secretion. This first triggering phase (Figure 1.5) starts with the ATP-
dependent closure of the KATP channel, which leads to the depolarization of the cell 
membrane, resulting in opening of voltage-dependent Ca2+ channels (VDCC) in the 
cell membrane, causing an influx of Ca2+. The subsequent increase in intracellular 
Ca2+ concentration [Ca2+]i triggers the exocytosis of insulin vesicles.77,78 The 
sustained augmentation phase of insulin secretion is independent of KATP channels. 
While the triggering phase can be induced by any stimulus that results in increased 
[Ca2+]i, the sustained phase relies on other secretagogues and thus requires the 
metabolism of glucose. In the β-cell, different pools of insulin vesicles are present. 
These pools include the intracellular reserve pool (~90%), the morphologically 
docked vesicles (~10%) and the readily releasable pool (RRP; ~0.3-2.2%). In the 
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first triggering phase, the vesicles from the RRP and the docked pool are secreted. 
In contrast, the sustained augmentation phase of insulin secretion is dependent on 
vesicle mobilization and priming from the reserve pool.77 The mechanisms 
underlying this phase are not well known. Current hypotheses include various factors 
playing a significant role in the sustained phase of glucose mediated insulin 
secretion, such as cytosolic long-chain acyl-CoA, the pyruvate-malate shuttle, 
glutamate export from mitochondria, and an increased ATP to ADP ratio as well as 
hormones, such as vasoactive intestinal peptide, glucagon-like peptide 1 (GLP-1), 
and glucose-dependent insulinotropic polypeptide (GIP).78,79 The finally secreted 
insulin has various major effects on muscle and adipose tissue, the lipid metabolism 
as well as the protein metabolism. For example, insulin increases glucose uptake 
and glycolysis in muscle and adipose tissue, decreases the rate of lipolysis in 
adipose tissue and increases the rate of protein synthesis in muscle, adipose tissue 
and liver.80 
 
Figure 1.5 Glucose metabolism in pancreatic β-cells and the first phase of glucose-
dependent insulin secretion. Glucose is entering the cell through GLUT-2, where it is 
further processed, which consequently leads to an increase in ATP resulting in closure of 
KATP channels. This leads to the depolarization of the cell membrane, resulting in opening of 
VDCC and subsequent increase in [Ca2+]i triggering the secretion of insulin.  
1.3.2 Diabetes 
Diabetes, often termed diabetes mellitus, is a diseases with one of the highest and 
fastest increasing morbidities worldwide.81 An estimated 422 million adults worldwide 
were suffering from diabetes in 2014, compared to 108 million in 1980. The global 
prevalence of diabetes was tremendously raised, and resulted in 1.5 million deaths 
in 2012, thus placing an enormous burden on today’s healthcare system.82 
Therefore, it has become a priority in the field of medical research to find ways to 
treat and cure diabetes. There are various clinical forms of diabetes referred to as 
Type 1 (T1D), Type 2 (T2D), gestational diabetes (GD) and so-called maturity onset 
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diabetes of the young (MODY). The most common forms are T1D and T2D, whereas 
GD, occurring in 2-5% of pregnant women, and MODY, which is caused by 
mutations in transcription factors essential for β-cell development, are rare forms of 
diabetes.69 However, β-cells are the focal point of disease development and 
progression of all forms of diabetes. A deficiency in functional pancreatic β-cells 
results in inadequate insulin supply and, consequently hyperglycemia, which in turn 
is connected to secondary disorders such as retinopathy83 and neuropathy.69,84  
1.3.2.1 Type 1 Diabetes 
T1D is an autoimmune disease characterized by an absolute deficiency of insulin 
resulting from specific destruction of insulin producing β-cells.69,85 T1D is prevalently 
diagnosed in children and adolescents, thus also termed juvenile-onset diabetes.86 
The onset of T1D is triggered by a combination of various factors, of which just a 
small portion is identified to date.87 One factor increasing the susceptibility to T1D is 
the inheritance through a series of genes. Variations in the human leukocyte antigen 
class II-locus on chromosome 6 accounts for approximately 50% of the genetic risk 
that leads to T1D. Other loci, such as insulin, protein tyrosine phosphatase, non-
receptor type 22, cytotoxic T-lymphocyte-associated protein 4, and interleukin-2 
receptor alpha chain, exhibit a smaller contribution.87,88 Most of the loci associated 
with T1D susceptibility are connected to immune responses, supporting the concept 
that genetic factors are involved in mechanisms that lead to abnormal immune 
responses.88 Genetic components are essential, but insufficient in explaining the 
immune pathogenesis of T1D, because the majority of people with mutations in 
these susceptibility genes never develop the disease.87 The second factor that plays 
a major role in the development of T1D is the exposure to different environmental 
factors, which, in combination with genetic susceptibility, trigger the onset of the 
disease. However, despite extensive research, the number of evaluated potential 
environmental influences is quite small. Investigated and correlated factors are, for 
example, a relative lack of vitamin D as well as viral infections.86,87 The final 
autoimmune response results from a failure of the immune system to distinguish 
between self and non-self-antigens, which leads to the loss of self-tolerance.69 T1D 
can be divided into two distinct stages, insulitis and diabetes. Insulitis is 
characterized by the infiltration of pancreatic islets by a heterogeneous population of 
leukocytes, where β-cell destruction is mostly mediated by CD4+ T helper and CD8+ 
T cells.85 In addition to T cells, antigen presenting cells (APCs), like macrophages 
and dendritic cells are also required for the autoimmune response. All these various 
immune cells that infiltrate the pancreatic islets release different inflammatory 
mediators, including cytokines and free oxygen radicals that further contribute to β-
cell destruction.69,89 Two different mechanisms for the initiation of β-cell death and 
inflammatory response have been reported. In the recognition based model (cell-cell 
contact), CD8+ T cells are directly activated by recognizing β-cell antigens, including 
peptides derived from insulin or glutamic acid decarboxylase, presented by major 
histocompatibility complex (MHC) I molecules. In the recognition-independent 
(cytokine activation) mechanism, β-cell antigens are taken up by local APCs, 
probably mature dendritic cells, in pancreatic islets and transported to the pancreatic 
lymph nodes where the antigens are processed and presented by MHC II, and in 
turn activate CD4+ T helper cells. These activated CD4+ T helper cells return to the 
pancreatic islets and re-encounter cognate antigens to initiate an inflammatory 
response, subsequently resulting in the local production of highly concentrated 
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proinflammatory cytokines.69,85 β-cells are finally destroyed by apoptosis induced 
through Fas receptor/Fas ligand and tumor necrosis factor receptor/ligand 
interactions, as well as by granzymes and perforin released from cytotoxic effector T 
cells. Thus, activated APCs and T cells, as well as cytokines secreted from these 
leukocytes, synergistically destroy β-cells in pancreatic islets.69,89 Continuous insulitis 
finally results in the development of full-blown autoimmune mediated T1D, due to the 
significant loss in insulin secreting β-cells. Prior to the first clinical symptoms of T1D, 
β-cell mass of pancreatic islets has already been reduced by ~70%.88 At this stage of 
the disease, exogenous insulin supply becomes imperative. 
1.3.2.2 Type 2 Diabetes 
In contrasts to T1D, T2D is mainly diagnosed in adults and its prevalence increases 
with age, which is why it was formerly also called adult-onset diabetes. Recent data, 
though, indicate that symptoms that characterize T2D are progressively being 
recognized in adolescents.69,82 T2D is the most common form of diabetes accounting 
for 85–95% of all diabetes cases and it is characterized by β-cell failure due to 
insulin resistance in the canonical insulin sensitive tissues including adipose tissue, 
skeletal muscle and liver.69,82,90,91 Symptoms are similar to those of T1D, but often 
less distinct. Thus the disease often remains undiagnosed for several years, until 
complications have already arisen.82 The process of T2D development can be 
separated in three major stages: susceptibility, β-cell adaptation and β-cell failure.91 
The susceptibility of individuals to develop T2D originates due to the interplay of 
genetic predispositions and environmental and metabolic factors.82,91 In general, the 
risk of developing T2D is influenced by factors such as ethnicity, family history of 
diabetes, and previous GD combined with increased age, overweight, unhealthy diet, 
lack of physical activity and smoking.82 Despite many factors contributing to the 
development of T2D the major risks factor remain obesity and insufficient physical 
activity. A big portion of the obese population develops insulin resistance over the 
years, which subsequently leads to an increased insulin demand to maintain glucose 
homeostasis. After the susceptibility stage, the β-cell adaptation stage follows. In this 
stage, β-cells try to compensate the elevated insulin demand by expansion of β-cell 
mass and an increase in insulin secretion.69,91 Ultimately, glucose homeostasis in 
these individuals can only be preserved at the expense of increased insulin levels by 
expanded insulin secretion and β-cell mass. The chronic exposure of β-cells to 
hyperglycemia (glycotoxicity) and elevated free fatty acids and lipid intermediates 
(lipotoxicity) triggered by obesity finally leads to β-cell failure. This stage is 
characterized by progressive loss of β-cell mass and function as well as possible 
dedifferentiation of β-cells, induced by a persistently harmful environment, eventually 
leading to the development of T2D.91 Although the biological and physiological 
mechanisms during the adaptation to obesity and insulin resistance are not entirely 
clear, several studies established the concept that the nutrient-regulated mechanistic 
target of rapamycin/ribosomal protein S6 kinase beta-1 signaling pathway negatively 
regulates insulin signaling by acting on insulin receptor substrate proteins and could 
therefore contribute to and partly explain some of the abnormalities that ultimately 
result in β-cell failure and the development of T2D in conditions of nutrient 
overload.91,92 
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1.3.2.3 Treatment options for diabetes 
The main treatment for T1D is currently the administration of exogenous insulin. This 
treatment mostly protects patients from nephropathy and retinopathy, but 
unfortunately it is not efficient in preventing the recurrence of hypoglycemic events, 
seizures, and coma. To date, one of the therapeutic approaches that have been 
reported to have the potential to cure T1D is pancreas transplantation.69 Pancreas 
transplantations in diabetic patients are divided into three categories (i) those 
performed simultaneously with kidney transplantation (75%), (ii) those transplanted 
after a previous kidney transplantation (18%), and (iii) pancreas transplantation 
alone (7%). The total number of pancreas transplantations steadily increased until 
2004, but although graft function improved significantly over the years since 2004, 
the number of transplantation has declined. Pancreas transplantation is mainly 
performed in patients suffering from a terminal stage of diabetes, including 
nephropathy and, making dialysis a necessity.93 Although whole pancreas 
transplantation can prolong and improve the quality of life of patients suffering from 
terminal diabetes, is the procedure controversial due to the need of major surgery 
and long-term immunosuppression. Thus, pancreatic islet transplantation is 
considered a less invasive and, consequently, safer alternative to both major surgery 
and lifelong insulin injections.69 The introduction of the Edmonton Protocol in 2000 
led to an enormous improvement in the procedure of islets transplantation. James 
Shapiro and colleagues demonstrated that all seven treated subjects were insulin 
independent for at least one year following pancreatic islet transplantation using the 
Edmonton Protocol, which includes the use a special sirolimus-based and steroid-
free immunosuppressive cocktail.94 Between 2000 and 2005 more than 470 patients 
with T1D have received islet transplants following the Edmonton Protocol, at 43 
institutions worldwide.95 Only a small portion of recipients became insulin 
independent after one transplant, while the majority needed two to three transplants 
in order to become fully insulin independent.96 On average, repeated infusions of 
islets obtained from two to four donors are needed until normoglycemia is achieved. 
In order to establish islet transplantation as a widely accepted treatment, it is 
essential that the donor to recipient ratio is brought down to 1:1.97 Another major 
concern about this procedure is the loss of insulin independence within five years 
after the procedure in the majority of the patients, as well as the risks of 
immunosuppressant side effects.95 The success of this approach is dependent on 
finding new ways to improve long-term islets functionality, the development of better 
and safer immunosuppressants, and the discovery of new approaches to overcome 
the non-proliferative status of β-cells ex vivo, in order to expand islets ex vivo prior to 
transplantation.95,98 In addition to research focusing on improving islets 
transplantation, such as finding new methods and sites of transplantation in the 
body,99,100 substantial research has been done to tackle T1D in different ways. 
These approaches include, for example, viral targeting of islet cells to express 
growth factors and growth factor receptors in order to increase islet survival and 
proliferation.101-103  
In contrast to T1D, for T2D very effective approaches are available to prevent the 
disease and to prevent complications and premature death that can result from all 
types of diabetes. These strategies include regular physical activity, wholesome 
food, avoiding overweigth, avoiding smoking, and the control of blood pressure and 
lipids.82 In addition to preventive actions, several drugs are on the market for T2D 
19 
 
that help to maintain glucose homeostasis. There are different classes of drugs 
available, some of them have been widely availabe for more than a decade, such as 
sulphonylureas, biguanides and thiazolidinediones.104  
Sulphonylureas act directly by triggering insulin release from the pancreatic β-cell. 
They occupy a specific site (SUR site) on the KATP channel, which leads to blockage 
of the channel, membrane depolarization and subsequent opening of calcium 
channels. This further results in exocytosis of insulin. Glibenclamide, gliclazide, 
glipizide and glimepiride are the primary sulphonylureas in current clinical use for 
T2D. Unfortunaetly, sulphonylureas show a progressive reduction in their effectivity 
during long-term use. This decline in effect is the result of a decrease in the 
insulin-producing capacity of pancreatic β-cell. Another adverse effect of 
sulphonylureas is the occurance of hypoglycaemic events. Sulphonylureas can be 
combined with a basal insulin injection to provide enhanced endogenous insulin 
secretion after meals. In addition to sulphonylureas, there are now many other 
choices for initial therapy of T2D, such as metformin and thiazolidinediones that 
affect insulin sensitivity by independent mechanisms.105 
Metformin is the most well-known representative of the biguanide family and is the 
drug that is most commonly administered as a first instance drug in T2D patients. In 
contrast to sulphonylureas, metformin does not directly act on insulin secretion. 
Mechanistically, metformin inhibits the mitochondrial complex I, thus reducing ATP 
and increasing AMP levels. Elevated AMP concentrations in the cell inhibit adenylyl 
cyclase activity, especially in response to glucagon binding to its receptors, which in 
turn downregulates the effects of glucagon.106,107  
Thiazolidinediones, such as rosiglitazone and pioglitazone are peroxisome 
proliferator-activated receptors γ (PPARγ) agonists and have been widely used to 
treat T2D for almost 20 years. PPARγ was the first gene identified to be related to 
T2D. PPARγ is a member of the nuclear hormone receptor superfamily and is 
expressed in adipose tissues and in low levels also in the liver and muscle.108,109 
Thiazolidinediones are classical insulin sensitizers and act to restore blood glucose 
to normal levels by increasing the insulin sensitivity of target tissues without the risk 
of causing hypoglycemia, thereby potentially rescuing the pancreatic islets from the 
burden of synthesizing and secreting more insulin and the consequent functional 
depletion.108 Mechanistically, thiazolidinediones regulate the expression of a panel of 
PPAR𝛾 downstream target genes associated with glucose and lipid metabolism, 
adipokine secretion, and inflammatory reactions in target tissues.109 Despite those 
major advantages of thiazolidinediones, rosiglitazone was removed from the market 
after 6 years because of successive detection of adverse events, such as increased 
cardiovascular risk, fluid retention, bone fractures, hepatotoxicity and body weight 
gain.110 Pioglitazone is still on the market but is marked for potentially increased risk 
for cardiovascular complications and bladder cancer. Thus, the clinical use of first-
generation full PPAR𝛾 agonists has been greatly restricted.108  
Incretin-related products are another approved treatment of hyperglycemia in T2D. 
They are designed to mimic or strengthen the action of GLP-1.104 GLP-1 acts 
through binding and activating the human GLP-1 receptor on both β- and α-cells to 
enhance glucose-dependent insulin and suppress glucagon secretion, respectively. 
It also slows gastric emptying, reduces food intake, increases β-cell mass, maintains 
β-cell function and improves insulin sensitivity.111 Incretin-based drugs act either on 
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the GLP-1 receptor directly, or the enzyme responsible for the degradation of GLP-1, 
dipeptidyl peptidase-4 (DPP-4.) DDP-4 inhibitors protect GLP-1 from rapid 
degradation resulting in potent and efficient glucose control and moreover they show 
protective actions against diabetic complications.112 
There is progressive research in various directions, for both T1D and T2D, to 
improve or to find new treatment options for T1D and T2D, including some less 
conventional methods. Some of these approaches employ optogenetic methods to 
overcome certain drawbacks of conventional methods. These approaches include 
light-controlled insulin secretion through the usage of channelrhodopsin113,114, light 
activated transgene (incretin) expression115 as well as light switchable incretin 
mimetics.116  
1.3.2.4 Growth factors and their cognate receptors as treatment options for 
diabetes 
Growth factors and their cognate receptors, growth factor receptors (GFRs), many of 
which are members of the RTK protein family, play a central role in the normal 
physiology as well as in the development and progression of various diseases.117 
RTKs are single-pass transmembrane proteins with an extracellular ligand-binding 
domain and an intracellular kinase domain. The human genome encodes more than 
50 RTKs that are grouped into 20 different families according to structural and 
sequence similarity.117 For many RTKs, binding of a polypeptide ligand to the 
extracellular domain leads to receptor dimerization and subsequent 
autophosphorylation of intracellular tyrosine residues, which act as docking sites for 
adaptor proteins and ’hubs’ to downstream signaling mediators. In this way, RTKs 
link extracellular stimuli to major intracellular signaling cascades such as the 
MAPK/Erk and the phosphatidylinositol-3 kinase/Akt (PI3K/Akt) pathway. Through 
these pathways RTKs control cell proliferation, survival, migration and invasive 
capacity.118 Numerous studies performed in cell and animal models have 
unequivocally demonstrated the contribution of growth factors, their cognate 
receptors and various associated signaling pathways (e.g. MAPK/Erk, PI3K/Akt) in 
the regulation of β-cell growth, survival, function and differentiation.119-122 Growth 
factors, such as hepatocyte growth factor (HGF), β-cellulin, fibroblast growth factor 
21, and glial cell line-derived neurotrophic factor, are efficacious in different models 
of diabetes and candidates for β-cell regeneration.119,120,123-126 As each of these 
factors is secreted, and can exogenously implement its action through their cognate 
receptors, they have the potential to be administered for treatment. Unfortunately 
there are some major drawbacks to this method. One is the non-specific effect of 
growth factors on other organs where receptors are present.120 Another one is the 
short half-life of exogenous growth factors in the blood circulation.119,127 However, 
the major disadvantage, of growth factors as therapeutic agents for diabetes is their 
frequent characterization as oncogene and their tumorigenic properties as a 
consequence of prolonged activation.119,128 For instance, HGF regulates intercellular 
mechanisms essential for beneficial effects in β-cells, but ubiquitously elevated HGF 
levels display tumorigenicity in a broad array of tissues in mouse models, suggesting 
that prolonged high levels of HGF, although therapeutically important, may have 
adverse consequences. In conclusion, temporary, local expression of growth factors 
or their receptors in β-cells may be a preferable therapeutic option.119  
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CHAPTER 2: AIM 
The potential of optogenetic techniques as therapeutic options is currently limited by 
various factors. First, the wavelengths used to activate the most common 
optogenetic tools make non-invasive light delivery to target tissues difficult. At the 
moment, mostly blue and green light is used to control optogenetic tools and these 
wavelengths have very limited tissue penetration.64,115,129,130 Second, optogenetics 
requires gene transfer, restricting its use as therapeutics as gene therapy is still 
associated with many risks.131-134 
The overall goal of this thesis is the development of new strategies to overcome the 
limitations of optogenetic approaches, with regard to light delivery to tissues and 
feasibility as therapeutic approach with a specific focus on cell regeneration. The 
overall goal can be divided into two parts. First, to overcome the limited light delivery 
to target tissues by engineering and characterizing red-light-activated growth factor 
receptors. Red light exhibits a much higher tissue penetration than other 
wavelengths of the visible spectrum. Second, to eliminate the necessity of gene 
therapy to make target tissues light sensitive, by identifying and investigating 
endogenous light-sensitive mechanisms and their potential to promote proliferative 
and pro-survival signals. 
A special focus lies on implementing these new light-based approaches in pancreatic 
β-cell systems, as pancreatic β-cells are the key players of diabetes. Diabetes is one 
of the most frequent and fastest growing diseases worldwide. Therefore, it has 
become a priority in the health-care field to find ways to treat and cure this disease.82 
Numerous studies performed in cell and animal models have unequivocally 
demonstrated the contribution of growth factors, their cognate receptors and various 
associated signaling pathways in the regulation of β-cell proliferation and 
survival.120,121,124,125,135 However, there are several drawbacks to growth factor 
therapies that have remained a theoretical exercise, such as the non-specific effects 
of growth factors as well as their tumorigenic properties.120,128,135 An optogenetic or 
optical approach of promoting the activation of proliferative and pro-survival signaling 
cascades can overcome these disadvantages of growth factors as therapeutic 
agents for diabetes by providing the required spatio-temporal precise activation.135 
The strategies established in this thesis additionally decrease optogenetic limitations 
such as non-invasive light delivery and gene transfer. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Animals 
CD-1 mice were purchased from Charles River at an age of 6 to 8 weeks and were 
used for primary islet isolation at an age of 7 to 12 weeks. C57BL/6J mice were bred 
within the breeding facility of IST Austria and were used at an age of 8 weeks only 
for primary islet isolation for OPN3-/- control experiments. OPN3-/- mice were 
generated in a C57BL/6J genetic background and were a gift from the laboratory of 
King-Wai Yau at the Johns Hopkins University School of Medicine. The Opn3−/− 
mouse line was generated by crossing an Opn3flox/flox mouse line, derived from 
embryonic stem cell clones, with a Sox2-Cre transgenic line, in which Cre 
recombinase was expressed globally in early embryos. The Opn3flox/flox construct 
included a targeting construct for inserting both a flippase recognition target (FRT) 
flanked-lacZ cassette upstream of exon 2 of the Opn3 gene, which was additionally 
flanked by a pair of loxP sites (Figure 3.1). A set of three primers was used to 
genotype the Opn3-/- mice: OPN3WT_F, OPN3-/-_F and OPN3_R (Table A1). A 
combination of OPN3WT_F and OPN3_R gave a 530 bp band for the WT allele, 
whereas a combination of OPN3-/-_F and OPN3_R gave a 670 bp band for the 
Opn3-/- allele.50 
All animals were housed within the breeding facility of IST Austria, which has been 
approved by the Austrian Federal Ministry of Science, Research and Economy. All 
animals were housed in commercially available individually ventilated cages–Type II 
(500 cm2) made of polysulfone under standard laboratory conditions (room 
temperature 22 ± 1°C; relative humidity 55 ± 10%; day/night rhythm of 12 hours) and 
supplied with standard diet (Altromin.1324 maintenance diet or Altr.1314 breeding 
diet) and autoclaved water ad libidum.  
 
Figure 3.1 Schematic representation of the Opn3flox/flox targeting construct.  
Through homologous recombination at the 5′ and 3′ arms, a FRT-lacZ cassette was inserted 
before exon 2 of the Opn3 gene. The exon is additionally flanked by loxP sites. Cre-
dependent recombination at these sites leads to the deletion of exon 2, which encodes 
almost three entire transmembrane domains of OPN3. Dark bars indicate exons. En2SA: 
mouse Engrailed2 intron splice acceptor; hActbP: human β-actin promoter; IRES: internal 
ribosome entry site; lacZ: β-galactosidase cDNA; neo: neomycin-resistance gene; pA: SV40 
polyadenylation site (illustration adapted from Buhr et al. 2015).50 
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3.1.2 Tissue culture 
Dulbecco's modified eagle medium (DMEM, Gibco/Thermo Fisher Scientific) 
Roswell park memorial institute 1640 medium (RPMI 1640, Gibco/Thermo Fisher 
Scientific) 
Connaught medical research laboratories medium, no glutamine (CMRL, 
Gibco/Thermo Fisher Scientific) 
CO2-independent medium (Gibco/Thermo Fisher Scientific) 
Leibovitz's L-15 Medium (Gibco/Thermo Fisher Scientific) 
Opti-MEM I® (Gibco/Thermo Fisher Scientific) 
Phosphate-buffered saline 1x (PBS, Gibco/Thermo Fisher Scientific) 
Polyethylenimine (PEI, Polysciences); PEI was dissolved in Milli-Q H2O at a 
concentration of 1mg/ml followed by sterile filtration through a 0.22 μm membrane.  
Lipofectamine® 2000 (Invitrogen/ Thermo Fisher Scientific) 
Fetal Bovine Serum (FBS, Gibco/Thermo Fisher Scientific); FBS was heat 
inactivated at 56°C for 35 minutes and stored at -20°C. 
Trypsin-ethylenediaminetetraacetic acid (0.25%), phenol red (Trypsin-EDTA) 
Gibco/Thermo Fisher Scientific) 
Acutase (Sigma) 
Penicillin-Streptomycin (Gibco/Thermo Fisher Scientific) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma) 
Sodium pyruvate (Gibco/Thermo Fisher Scientific) 
L-Glutamine (Gibco/Thermo Fisher Scientific) 
β-Mercaptoethanol (Sigma) 
Poly-L-ornithine (PLO, Sigma); The working dilution was 1:25 in Milli-Q® H2O. 
Cryotubes Nunc™, sterile (A. Hartenstein) 
35 mm cell culture dishes, NuncTM (for HEK293 cells and HeLa cells, Nunc/Thermo 
Fisher Scientific) 
35 mm cell culture dishes, Falcon® (for INS-1E cells, BD Falcon) 
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96-well clear bottom plates (Greiner Bio-One) 
T-75cm2 tissue culture flask (for HEK293 cells and HeLa cells, TPP) 
T-25cm2 tissue culture flask (for HEK293 cells and HeLa cells, TPP)  
T-75cm2 tissue culture flask (for INS-1E cells, BD Falcon) 
T-25cm2 tissue culture flask (for INS-1E cells, BD Falcon)  
4',6-Diamidino-2-phenylindole dihydrochloride (DAPI, Life technologies/ Thermo 
Fisher Scientific); The working dilution was 1:4000 in PBS. 
Mowiol® 4-88 (Sigma) 
3.1.3 Molecular biology 
pGL4.33 vector (Promega) 
RNase Away Reagent (Sigma) 
Ultrapure nuclease-free water (Gibco/Thermo Fisher Scientific) 
DNAseI and DNAseI buffer (Sigma) 
Random hexamer primer (Thermo Fisher Scientific) 
5x RevertAid reaction buffer (Thermo Fisher Scientific) 
Deoxyribonucleotide triphosphates (dNTPs, New England Biolabs) 
RiboLock RNAse inhibitor (Thermo Fisher Scientific) 
RevertAid reverse transcriptase (RT, Thermo Fisher Scientific) 
DpnI (New England Biolabs) 
Alkaline Phosphatase, Calf Intestinal (CIP, New England Biolabs) 
PfuX polymerase and 10x PfuX buffer (Jena Bioscience) 
Dimethylsulfoxid (DMSO, Sigma) 
NEB restriction enzymes and corresponding buffers (New England Biolabs) 
T4 ligase and corresponding 10x T4 buffer (New England Biolabs) 
1 kbp DNA ladder (New England Biolabs) 
100 bp DNA ladder (New England Biolabs) 
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Clarity Western ECL Substrate (Bio Rad) 
Agarose Standard (Carl Roth) 
Agarose NEEO Ultra-Qualität (Carl Roth); only used for gel purification 
6x loading dye Orange G (Sigma); 0.15% Orange G in 30% glycerol 
LB ampicillin agar plates (Media kitchen IST Austria) 
50x Tris-acetate-EDTA buffer (TAE buffer, Media kitchen IST Austria) 
XL10-Gold® Ultracompetent E. coli cells (Agilent Technologies) 
3.1.4 Antibodies 
3.1.4.1 Primary antibodies 
Anti phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling) 
Anti phosph-Akt (Ser473)(D9E)XP rabbit mAB (Cell Signaling) 
Anti Erk2 antibody (K-23) (Santa Cruz Biotechnology) 
Anti Akt antibody (Cell Signaling) 
Anti calnexin antibody (H-70) (Santa Cruz Biotechnology) 
Anti vinculin antibody (Abcam) 
Anti insulin antibody (R&D Systems) 
3.1.4.2 Secondary antibodies 
Goat anti rabbit IgG(H+L)-HRP conjugated (1706515, Bio Rad) 
Alexa Fluor555 goat anti rat IgG (A-21434, Thermo Fisher Scientific) 
3.1.5 Miscellaneous 
Altromin1314 and 1324 diet (Altromin Spezialfutter GmbH&Co.KG) 
Beetle luciferin (Promega) 
Bovine Serum Albumin (BSA; Sigma) 
Bromophenol blue (Sigma) 
Calciumchlorid-dihydrate (CaCl2-2H2O, Sigma) 
Clarity Western ECL Substrate (Bio Rad) 
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Collagenase P (Sigma) 
Complete™, EDTA-free Protease Inhibitor Cocktail (Sigma) 
Ethanol 99.9% (Sigma) 
Ethylenediaminetetraacetic acid (EDTA, Roche) 
Fibroblast growth factor 2 (FGF2, Sigma) 
Glucose D(+) (Sigma) 
Glycine (Sigma) 
Guanidine hydrochloride (Guanidine-HCl, Sigma) 
Glycerol (Sigma) 
Phycocyanobilin (PCB, Livchem Logistics) 
9-cis retinal (Sigma) 
Isopropanol (Sigma) 
Magnesium chloride hexahydrate (MgCl2-6H2O, Sigma) 
Milli-Q® H2O (Media kitchen IST Austria) 
Methanol 99.9% (Sigma) 
Paraformaldehyde (PFA, Sigma) 
Potassium chloride (KCl, Sigma) 
Precision PLUS protein WesternC standard (Bio Rad) 
Precision protein StrepTactin-HRP conjugated (Bio Rad) 
Sodium hydroxide (NaOH, Sigma) 
Sodium dodecyl sulphate (SDS, Sigma) 
Sodium deoxycholate (Sigma) 
Sodium chloride (NaCl, Sigma) 
Synthetic genes (CPH1So, GloSensor-22F, Epoch Life Science, Inc.) 
Trametinib (GSK1120212, Selleckchem/Absource Diagnostics GmbH) 
Thiazolyl blue tetrazolium bromide (Sigma) 
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Triton X-100 (Sigma) 
Trizma hydrochloride (Tris-HCl, Sigma) 
Trizma base (Sigma) 
4–20% Mini-PROTEAN® TGX™ Precast Protein Gels, 10-well (Bio Rad) 
15 ml falcon tube (BD Falcon) 
1.5 ml microcentrifuge tube (Eppendorf)  
3.1.6 Buffers and solutions 
DMEM complete medium  
DMEM 
10% FBS 
100 U/ml Penicillin  
0.1 mg/ml Streptomycin 
INS-1E complete medium  
RPMI-1640 
10% FBS 
100 U/ml Penicillin 
0.1 mg/ml Streptomycin 
10 mM HEPES 
1 mM Sodium pyruvate 
2 mM L-Glutamine  
50 μM β-Mercaptoethanol 
Murine islets complete culture medium  
RPMI-1640 
10% FBS  
100 U/ml Penicillin  
0.1 mg/ml Streptomycin 
Human islets complete culture medium  
CMRL  
10% FBS 
100 U/ml Penicillin 
0.1 mg/ml Streptomycin  
2 mM L-Glutamine 
DMEM transfection medium 
DMEM 
5% FBS   
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INS-1E transfection medium  
RPMI-1640 
5% FBS 
10 mM HEPES 
1 mM Sodium pyruvate 
2 mM L-Glutamine  
50 μM β-Mercaptoethanol 
DMEM reduced serum medium 
DMEM 
0.5% FBS  
100 U/ml Penicillin  
0.1 mg/ml Streptomycin 
INS-1E reduced serum medium  
RPMI-1640 
0.1% FBS 
100 U/ml Penicillin 
0.1 mg/ml Streptomycin 
10 mM HEPES 
1 mM Sodium pyruvate 
2 mM L-Glutamine  
50 μM β-Mercaptoethanol 
CO2-independent reduced serum starve medium  
CO2-independent medium  
0.5% FBS 
2 mM L-Glutamine 
100 U/ml Penicillin  
0.1 mg/ml Streptomycin 
Leibovitz's L-15 complete medium  
Leibovitz's L-15 Medium  
10% FBS 
100 U/ml Penicillin  
0.1 mg/ml Streptomycin  
RIPA buffer 
150 mM NaCl 
1.0% Triton X-100 
0.1% SDS 
50 mM Tris-HCl, pH 8.0 
0.5% Sodium deoxycholate  
Complete™, EDTA-free Protease Inhibitor Cocktail (one tablet for 50ml) 
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Loading buffer (Laemmli 4X) 
40% Glycerol 
240 mM Tris-HCl pH 6.8 
8% SDS 
0-04% Bromophenol blue 
5% β-Mercaptoethanol  
SDS-running buffer (10x) 
30,3 g/L Tris-HCl 
144 g/L Glycine 
1% SDS 
pH 8.3 
Diluted to 1x before final use. 
Transfer buffer (20x) 
58.6 g Glycine 
116.2 g Tris-HCl 
37.5 ml 20% SDS 
Milli-Q® H2O to 1 L 
Transfer buffer (1x) 
50 ml 20x Transfer Buffer 
200 ml Methanol 
750 ml Milli-Q® H2O 
Tris-buffered saline (TBS, 10x)  
80 g/L NaCl 
2 g/L KCl 
30 g/L Trizma base 
pH to 7,4 
Milli-Q® H2O to 1 L 
TBST 
999 ml TBS (1x) 
1 ml Tween 
PBST 
999 ml PBS (1x) 
1 ml Tween 
Blocking buffer for immunoblotting 
5 g Skinny milk powder or BSA 
100 ml TBST  
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Blocking buffer for Click-iT® Plus EdU Alexa Fluor® 488 Imaging  
0.1 g BSA  
10 ml PBST 
Krebs buffer (KRB)  
7.13 g/L NaCl  
0.35 g/L KCl  
0.224 g/L MgCl2-6H2O 
0.37 g/L CaCl2-2H2O 
2.38 g/L HEPES 
pH adjust pH to 7.4 with NaOH 
Sterile filtered through a 0.22-μm membrane. 
Sterile 1.65 M Glucose D(+) solution 
29.73 g/L Glucose D(+)  
Milli-Q® H2O to 100 ml 
Autoclaved 
Stimulation buffer (16.7 mM glucose in KRB) 
25 ml KRB  
0.5% BSA 
0.250 ml sterile 1.65 M Glucose D(+) solution 
Basal buffer (3.3 mM glucose in KRB) 
75 ml KRB  
0.5% BSA 
0.150 ml sterile 1.65 M Glucose D(+) solution 
Acidic isopropanol  
1 ml 1 M HCL  
9 ml Isopropanol 
Acidic ethanol 
75 ml Ethanol 100%  
23.5 ml Milli-Q® H2O 
1.5 ml concentrated HCl 
4% Paraformaldehyde fixation solution  
90 ml Milli-Q® H2O 
4 g PFA  
10 ml PBS (10x) 
Water was heated to 60°C and PFA was added. NaOH was added dropwise until the 
solution became clear. pH was adjusted to 7.4 with HCl. Finally 10 ml PBS (10x) 
were added. 
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A+AB buffer 
135 mM NaCl 
5.6 mM KCl 
1.2 mM MgCl2-6H2O 
1.28 mM CaCl2-2H2O 
10 mM HEPES 
3 mM Glucose D(+) 
1% (V/V) Penicillin/Streptomycin 
0.1 mg/ml BSA 
Before adding Penicillin/Streptomycin and BSA the pH of the solution was adjusted 
with NaOH to pH 7.4. 
Sterile filtered through a 0.22 μm membrane. 
Collagenase solution 
2 mg Collagenase P (1.9 U/mg)  
2 ml A+AB buffer 
 
Extraction buffer 
100 mM Tris-HCl  
4 mM EDTA  
6 M Guanidine-HCl 
pH7.8 
3.1.7 Kits 
Total RNA Purification Kit (Jena Bioscience)  
QIAquick Gel Extraction Kit (Qiagen) 
PCR Purification Kit (Jena Bioscience) 
Plasmid MiniPrep Kit (Jena Bioscience) 
PathDetect Elk1 trans-Reporting System (Agilent Technologies) 
One-Glo Assay System (Promega) 
Click-iT® Plus EdU Alexa Fluor® 488 Imaging Kit (Life Technologies) 
Human Insulin ELISA Kit-80-INSHU-E01.1-AL (ALPCO/BioCat) 
Pierce™ BCA Protein Assay Kit (Fisher Thermo Scientific)  
ATP Determination Kit (Invitrogen/ Fisher Thermo Scientific) 
3.1.8 Equipment 
Hemocytometer-Neubauer chamber improved (Marienfeld-Superior) 
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Molecular Imager® VersaDoc™MP Substrate (Bio Rad) 
Gel Doc™ XR  
Thermocycler C1000TM (BioRad) 
High intensity LEDs HLMP-CE35 (Broadcom) 
X4-Life RGB LED-stripes SMD5050 (12 V, 1 m and 5 m, RGB X4, Conrad) 
BioTek Synergy H1 microplate reader (BioTek) 
Power meter (PM120VA, Thorlabs). 
Lamp illuminator with rapid filter exchange (DG4plus, Sutter instruments) 
Microscope Olympus SZ51 (Olympus) 
Water bath TW 8 (Julabo) 
Thermomixer comfort (Eppendorf) 
Eppendorf centrifuge 5424R (Eppendorf) 
Multifuge X3R (Fisher Thermo Scientific) 
EVOS® fluorescence microscope (Fisher Thermo Scientific) 
LSM 700 inverted (Zeiss) 
Standard scissors-straight sharp/blunt (Fine Science Tools) 
Tungsten-carbide iris scissors (Fine Science Tools) 
Narrow pattern forceps (Fine Science Tools) 
Small straight clamp (Fine Science Tools) 
Large curved clamp (Fine Science Tools) 
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3.2 Molecular biology methods 
3.2.1 RNA extraction and DNase I digest 
The extraction of total RNA was performed using the Total RNA Purification Kit 
according to the manufacturer’s instructions. The RNA was eluted in 30 µl 
nuclease-free water, placed immediately on ice and further processed by DNase I 
digest. For the digest, 30 µl of eluted RNA (not more than 1 µg) was mixed with 4 µl 
10x DNaseI buffer, 1 µl DNAseI and 5 µl nuclease-free water. The reaction was 
incubated for 30 minutes at 37°C followed by the addition of 2 µl 50 mM EDTA and 
10 minutes incubation at 65°C to inactivate the DNaseI. After inactivation, the RNA 
was immediately placed on ice. For RNA extraction from islets, 70 to 100 murine 
islets or human islet equivalents (IEQs) were used. For cell lines, RNA was extracted 
from 1x106 cells.  
3.2.2 cDNA synthesis 
All steps of the cDNA synthesis were prepared on ice. 3 µL of random hexamer 
primer were added to the inactivated DNAseI reaction and incubated for 5 minutes at 
70°C. For a minus RT control (-RT), an additional reaction was prepared. After the 
random hexamer primer incubation, 13 µL of 5x RevertAid reaction buffer, 5 µL of 10 
mM dNTPs and 2 µL of RiboLock RNAse inhibitor were added to the reactions and 
incubated for 5 minutes at 25°C. After 5 minutes, 1 µL RT was added to the reaction, 
but not to the -RT control, and incubated for 10 minutes at 25°C. Then the reactions 
were incubated for 1 hour at 42°C followed by 10 minutes at 70°C. Afterwards the 
cDNA was immediately placed on ice or frozen at -20°C. 
3.2.3 Polymerase chain reaction 
Polymerase chain reaction (PCR) was carried out using a thermocycler. The PCR 
mix was prepared as outlined in Table 3.1. Primers were designed to have a melting 
temperature (Tm) of ∼72°C according to Equation 3.1. Details of primers are given in 
appendix Table A2. Standard PCRs were performed with the conditions outlined in 
Table 3.2, for RT-PCR the conditions are outlined in Table 3.3 and primers are listed 
in Table A3. After completion of a standard PCR, the DNA template of the PCR was 
eliminated by enzymatic digest with 1 µl of DpnI for 1.5 hours at 37°C followed by a 
purification using the PCR Purification Kit according to the manufacturer’s 
instructions. The products of a RT-PCR were analyzed by agarose gel 
electrophoreses, followed by sequencing. 
Equation 3.1 Calculation of Tm of PCR primer  
Tm = 81.5+0.41 x ((GC units/ length) x 100)-(675/ length)-((mismatches/ length) x 
100) 
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Table 3.1 Reagents for PCR  
Reagents Volume 
PfuX polymerase 0.5 µl 
PfuX buffer (10x) 5 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
DMSO 1 µl 
Plasmid DNA (20 ng/µl)/cDNA 1 µl/3 µl 
dNTPs (10 mM) 1 µl 
Nuclease-free water  Fill up to 50 µl 
Table 3.2 Standard PCR conditions 
Steps Temperature (°C) Duration (min:sec) Number of cycles 
Pre-denaturation 95 2:00 1 
Denaturation 95 0:20 
34 Annealing 56  0:20 
Elongation 68 1:00/kb  
Extension 68 1:00/kb  1 
Table 3.3 RT-PCR conditions 
Steps Temperature (°C) Duration (min) Number of cycles 
Pre-denaturation 95 2:00 1 
Denaturation 95 0:20 
34 Annealing 58 0:20 
Elongation 68 0:30 
Extension 68  1:00 1 
3.2.4 Site-directed mutagenesis 
To perform a site-directed mutagenesis, a pair of complementary mutagenic primers 
was designed to amplify the entire plasmid resulting in a recircularized product. 
Primers were designed as for a standard PCR using Equation 3.1 and the details of 
used primers are in appendix Table A2. The reagents of the reaction mix were 
identical to those of a standard PCR (Table 3.1) and the reaction conditions 
mentioned in Table 3.4 were used. After completion of the reaction, the DNA 
template was eliminated by enzymatic digest with 1 µl of DpnI per reaction for 1.5 
hours at 37°C. After DpnI digest, the circular product was directly inserted into 
competent Escherichia coli (E. coli, XL-10 Gold) by incubating 1.2 µl of the reaction 
product with the cells for 30 minutes on ice. After 30 minutes the transformed cells 
were plated on a prewarmed LB-ampicillin plate and incubated overnight at 37°C. 
The workflow of a site-directed mutagenesis is outlined in Figure 3.2. 
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Figure 3.2 Work flow of site-directed mutagenesis. First, mutant strand synthesis is 
carried out by performing thermal cycling to denature the DNA template, anneal mutagenic 
primers, containing the desired mutation, and elongation using a high-fidelity DNA 
polymerase. Second, the template plasmid is enzymatically digested by DpnI. Third, 
competent E.coli cells were transformed with the mutated plasmid and finally transferred on 
LB-ampicillin plates and incubated overnight at 37°C. 
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Table 3.4 Site-directed mutagenesis reaction conditions 
 Temperature (°C) Duration (min:sec) Number of cycles 
Pre-denaturation 95 2:00 1 
Denaturation 95  0:20 
21 Annealing 56 0:20 
Elongation 68 1:00/kb  
Extension 68 1:00/kb  1 
3.2.5 DNA digest using restriction enzymes 
PCR products flanked with restriction sites or plasmids were digested using 
restriction enzymes for 1 hour at 37°C and further purified with the PCR Purification 
Kit according to the manufacturer’s instructions. Exceptionally, DNA digests with the 
restriction enzyme SgrAI were performed for 30 minutes at 37°C, followed by a gel 
purification step using the QIAquick Gel Extraction Kit according to the 
manufacturer’s instructions. For enzymatic digests, restriction enzymes and the 
corresponding buffers from New England Biolabs were used. The reaction was 
prepared as outlined in Table 3.5. Digested backbone plasmids were additionally 
treated with 1 µl CIP for 1.5 hours at 37°C. The CIP treatment catalyzed the removal 
of the 5´ phosphate groups from DNA, in order to avoid self-ligation and therefore 
decrease the vector background. Digested products were further processed in 
ligations. 
Table 3.5 Composition of digest reactions 
Reagents Amount 
Nuclease-free water Fill up 30 µl 
10x NEB buffer (corresponding to restriction enzyme) 3 µl 
Restriction enzyme 1 µl 
DNA 1500 ng  
3.2.6 Ligation 
Enzymatically digested plasmids and PCR products were ligated at a plasmid to 
insert ratio of 1:4 using T4 ligase. The ligation reaction was prepared as outlined in 
Table 3.6. As a control an additional reaction without insert was prepared. The 
ligation reactions were incubated for 3 hours at room temperature or 18 hours at 
4°C. Transformation, after ligation, was performed as described in section 3.2.4. 
Table 3.6 Reagents of ligation 
Reagents  Amount 
Nuclease-free water Fill up to 20 µl 
T4 ligase buffer (10x) 2 µl 
T4 ligase 1 µl 
Plasmid 50 ng 
Insert 4 times plasmid amount 
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3.2.7 Agarose gel electrophoresis 
A 1% gel was prepared for checking PCR products and for gel extraction, for RT-
PCR analysis a 2% agarose gel was prepared. For gel extraction, the PCR product 
was mixed with 10 µl 6x loading dye and loaded onto the gel. For standard PCR 
products and RT-PCR products, 5 µl of the product was mixed with 4 µl 6x loading 
dye and 16 µl H2O. For the DNA ladder, 1 µl was mixed with 4 µl 6x loading dye and 
20 µl H2O. Twenty µl of each sample was loaded onto the gel and all samples were 
run at 100 volt (V) for 15 minutes. Gels were visualized using Gel Doc.  
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3.3 Genetic engineering  
3.3.1 Engineering of expression plasmids of phytochrome sensory 
domains 
The gene fragment coding for the sensory domain of the phytochrome, CPH1 from 
Synechocystis PCC6803 (CPH1S) was amplified from a genomic DNA library using 
PCR (oligonucleotides 1 and 2, Table A1). In addition, the gene fragment for CPH1S 
was synthesized with mammalian codon optimization (CPH1So) according to the 
supplier’s recommendation and amplified using a PCR (oligonucleotides 3 and 4, 
Table A1). In order to perform expression as well as cytotoxicity tests in mammalian 
cells, an expression plasmid based on pcDNA3.1(-) was used in which a BspEI 
restriction site was placed after the fluorescent protein mVenus and a glycine- and 
serine-rich linker.136 CPH1S and CPH1So were inserted into this plasmid after PCR 
amplification by using the restriction enzyme XmaI (Figure 3.3 A). 
3.3.2 Engineering of red-light-activated RTKs 
To generate a red-light-activated murine fibroblast growth factor receptor 1 
(mFGFR1-CPH1So, Figure 3.3 B), the codon optimized phytochrome sensory 
domain, CPH1So, was inserted into a mFGFR1 construct that was described 
previously in Grusch et al. 2014136 using a PCR and the restriction enzyme XmaI 
(oligonucleotides 3 and 4, Table A2). This construct contained the complete 
intracellular domain of mFGFR1, a myristoylation membrane anchor and a HA-
epitope (Figure 3.2 B). For multi-color fluorescent reporter assays, the CMV 
promoter of the mFGFR1-CPH1So expression vector was truncated for lower 
expression137 using an inverse PCR with phosphorylated primers (oligonucleotides 5 
and 6, Table A1) followed by blunt end ligation. Point substitutions in mFGFR1-
CPH1So (Y271F, Y272F and R195E; numbered relative to start methionine of 
red-light-activated mFGFR1) were introduced using site-directed mutagenesis 
(oligonucleotides 11-14, Table A1). The red-light-activated rat tropomyosin receptor 
kinase B (rtrkB-CPH1So, Figure 3.3 B) was generated using an inverse PCR on 
mFGFR1-CPH1So (oligonucleotides 7 and 8, Table A1). By using PCR amplification 
the mFGFR1 intracellular domain was replaced and a linear double-stranded DNA 
product with terminal SgrAI restriction sites was generated. The PCR product was 
digested with SgrAI, ligated and propagated in E. coli cells. The rtrkB intracellular 
domain was then inserted using a PCR and the restriction enzyme BspEI and AgeI 
(oligonucleotides 9 and 10, Table A1). A point substitution in rtrkB-CPH1So (K131A, 
numbered relative to start methionine of red-light-activated rtrkB) were introduced 
using a site-directed mutagenesis (oligonucleotides 15 and 16, Table A1). 
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Figure 3.3 Expression plasmids (A) Example of expression plasmid used for expression 
and cytotoxicity tests of phytochrome sensory domains. The plasmid is based on 
pcDNA3.1(-) including mV followed by CPH1So under the control of a CMV promoter. (B) 
Expression plasmid of mFGFR1/rtrkB-CPH1So containing the intracellular RTK domain, a 
myristoylation membrane anchor, the CPH1So domain and a Ha-Tag 
3.3.3 Engineering of fluorescence reporters 
Fluorescence transcriptional reporters were generated by Alexandra-Madelaine 
Tichy (IST Austria), by first removing the luciferase gene from the pGL4.33 vector 
using an inverse PCR and the restriction enzyme AscI (oligonucleotides 17 and 18, 
Table A1). Then mCherry was inserted using PCR, followed by an enzymatic digest 
with AscI (oligonucleotides 19 and 20, Table A1). The mCerulean3-N1 expression 
vector (Addgene # 54730) was used as a fluorescence viability reporter in multi-color 
fluorescent reporter assays.  
3.3.4 Engineering of real-time cAMP sensor 
A genetically-encoded real-time cAMP sensor (GloSensor-22F)138 was obtained as a 
synthetic gene and subcloned into pcDNA3.1(-) using NheI and KpnI restriction 
enzymes by Catherine McKenzie (IST Austria). 
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3.4 Tissue culture methods 
3.4.1 Description of cell lines 
Three different cell lines were used as cellular models for different experimental 
approaches. I) Human Embryonic Kidney (HEK) 293 cells were derived in 1971, from 
a healthy human embryonic kidney transformed by sheared adenovirus 5 DNA.139 
HEK293 cells were used as model system for various studies of this thesis; 
especially in experiments were transfection was necessary, because of their reliable 
growth and propensity for transfection. II) HeLa cells are human epithelial cells 
derived from cervical cancer cells, 1951. HeLa cells are the oldest and most 
commonly used human cell line.140 The cell line was used as an additional cell line to 
study light effects on mammalian cells. III) INS-1E cells have the characteristics of 
pancreatic β-cells, including a high insulin content and responsiveness to glucose. 
This cell line was clonal isolated from INS-1 cells, which are derived from a rat 
insulinoma induced by X-ray.141 INS-1E cells were used in this project as a model of 
pancreatic β-cells to study red-light-dependent signaling activation through 
mammalian tissue and to study the general effect of light on mammalian tissues. 
3.4.2 Maintenance and storage of cell lines 
HEK293 cells and HeLa cells were cultured in DMEM complete medium. INS-1E 
cells were cultured in INS-1E complete medium. All cells were cultured in a 
humidified incubator with 5% CO2 atmosphere at 37°C and they were subcultured 
two to three times a week depending when they reached 90-100% confluency. For 
subculturing, the medium was removed and the cells were washed once with PBS. 
Then cells were detached by 1 ml trypsin/EDTA for 3 minutes at 37°C, followed by 
the addition of 5 ml complete medium and the transfer of the cell suspension into a 
15 ml falcon tube, which was centrifuged for 5 minutes at 700 rpm. The supernatant 
was removed and the cell pellet was resuspended in 5 ml complete medium. 0.5 ml 
of the cell suspension was transferred to a new T-75cm2 tissue culture flask 
containing 10 ml complete medium.  
For cryopreservation and storage of cells, the same procedure as for subculturing 
was implemented, but the cell pellets were resuspended in freezing medium 
(complete culture medium supplemented with 10% DMSO) instead of complete 
medium. For HEK293 and HeLa cells 1 ml of cell suspension was transferred to a 
cryotube which was placed for 24 hours at -80°C and subsequently transferred to a 
liquid nitrogen storage vessel. For INS-1E cells, the cryotube containing 1 ml of cell 
suspension was first placed for 6 hour at -20°C, then for 24 hours at -80°C and 
subsequently transferred to a liquid nitrogen storage vessel for long-term storage. 
Cell lines were thawed by placing them in a 37°C water bath until the cell suspension 
was completely thawed. Cells were further transferred to a 15 ml falcon tube 
containing 10 ml pre-warmed complete medium, which was centrifuged for 5 minutes 
at 700 rpm. Cell pellets were resuspended in 5 ml complete medium and transferred 
to a T-25cm2 tissue culture flask. 
3.4.3 Cell quantification 
Before cell quantification, the same procedure as for subculturing was followed. After 
resuspending the cell pellet in 5 ml complete medium, a 1:10 dilution of the cell 
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suspension was prepared and 10 µl of this dilution were transferred to one side of a 
hemocytometer. The number of cells was determined by counting four 1 mm2 
squares of a hemocytometer and using Equation 3.2. 
Equation 3.2 Cell concentration per ml 
Cells/ml = Average number of cells per 4 squares counted x the dilution factor x 104 
3.4.4 Transfection of cell lines 
Cells were either transfected using PEI or Lipofectamine® 2000 as transfection 
reagent following the same protocol. Cells were either seeded 16 hours before 
transfection or directly before transfection. First, transfection reagent was mixed with 
Opti-MEM I® to a total volume of 25 µl/96-well or 125 µl/35 mm dish and incubated 
for 5 minutes at room temperature. During incubation, DNA was mixed with Opti-
MEM I® to a total volume of 25 µl/96-well or 125 µl/35 mm dish (Table 3.7). After 5 
minutes the transfection reagent/Opti-MEM I® mixture was combined with the 
DNA/Opti-MEM I® sample and incubated for 20 minutes at room temperature. After 
20 minutes the mixture was added to the cells seeded in appropriate transfection 
medium. Six hours after transfection medium was replaced with appropriate medium.  
Table 3.7 Reagents for transfection  
Reagents  96-well 35 mm dish 
DNA  ~200 ng ~2500 ng 
PEI (1 µg/µl) / Lipofectamine® 2000 (1mg/ml) 1 µl / 0.5 µl 20 µl / 10 µl 
Opti-MEM I® (fill up to) 50 µl 250 µl 
3.4.5 Expression and cytotoxicity test of phytochrome sensory 
domains in HEK293 cells 
To test expression and cytotoxicity of phytochrome sensory domains 5 x 104 
HEK293 cells were seeded in 100 µl DMEM transfection medium in each well of a 
PLO-coated 96-well clear bottom plate. HEK293 cells were transfected with 200 ng 
total plasmid (5-10 ng expression plasmid filled up with empty vector to 200 ng). The 
investigated expression plasmids were mV-CPH1S, mV-CPH1So and previously 
described mV-FKBP.136 Six hours after transfection the medium was replaced with 
DMEM complete medium. Thirty hours after transfection expression was assessed 
by replacing medium with PBS and measuring fluorescence (mV: λ Ex/Em = 495/528 
nm) in a microplate reader. After fluorescence measurement, cytotoxicity of 
phytochrome sensory domains was assessed in HEK293 cells expressing mV-
CPH1S, mV-CPH1So and mV-FKBP using a colorimetric-based assay to detect 
cellular metabolic activity (MTT assay). In detail, after fluorescence measurement 
cells were incubated for 2 hours with 0.5 mg/ml thiazolyl blue tetrazolium bromide 
dissolved in PBS followed by lysis with 70 µl acidic isopropanol. Finally, absorbance 
at 570 nm and 690 nm was measured in the microplate reader and cell viability was 
determined by Equation 3.3. 
Equation 3.3 Cell viability 
Cell viability = Absorbance 570nm – Absorbance 690nm (background)  
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3.5 Tissue preparations 
3.5.1 Preparation of synthetic tissues 
To pretest whether red-light-activated RTKs allowed non-invasive signaling 
activation in mammalian tissues, agarose gels stained with different dyes termed 
synthetic tissues, whose spectral properties matched those of human skin, skull and 
muscle, were prepared.142-144 Synthetic tissues were prepared by supplementing 
high purity 2% agarose gels with dyes depending on the tissue type (Table 3.8). The 
dyes were added to the liquid gel and mixed thoroughly until the dyes were 
homogenously distributed. The dye supplemented gel was poured into a transparent 
container having the same dimensions as a 96-well plate and was allowed to solidify. 
The walls of the container were covered with light-impermeable tape in order to allow 
light transmission just through the synthetic tissue. Synthetic skin and muscle were 
generated by supplementing 104.5 ml gel with different amounts of tartrazine and 
amaranth. Synthetic skull was generated by supplementing 31.4 ml gel with 
tartrazine, amaranth, allura red AC, prussian blue and brilliant blue (Table 3.8). 10 
mm of synthetic tissue corresponded to 10 mm of animal tissue, except for skin 
which has 20-fold higher absorption; in this case, 10 mm of synthetic tissue 
corresponded to 0.5 mm of mammalian skin.  
Table 3.8 Dye composition of synthetic tissues mimicking absorption spectrum of 
different mammalian tissues. 
Tissue type Tartrazine 
(µg) 
Amaranth 
(µg) 
Allura red 
AC (µg) 
Prussian 
blue (µg) 
Brilliant 
blue 
(µg) 
Skin 50 3 - - - 
Muscle 15 15 - - - 
Skull 75 10 55 25 50 
3.5.2 Determination of light transmission through mouse tissue 
To determine light transmission properties of different light wavelengths (λ = 470 nm, 
545 nm, 640 nm) through mammalian tissue, light penetration through murine head 
and abdomen was determined (Figure 3.4 A). For measuring light penetration 
through head, the lower jaw and the palate bone of shaved mouse heads were 
removed to create an opening. Light that penetrated through the shaved scalp, the 
skull and the whole brain was measured. For mouse abdomen, the shaved mouse 
torsos were opened and light that penetrated through shaved skin, fat, muscle, spine 
and organs was measured. A DG4plus lamp was used as illumination source for 
these experiments. A dish covered with light-impermeable tape excluding a defined 
window was placed above a sensor connected to a power meter (Figure 3.4 B). 
Three measurements were acquired each first without sample to determine the initial 
light intensity, I0, in µW/cm2 and then with the sample to determine transmission, I, in 
µW/cm2. Percentage of light transmission was calculated by Equation 3.4.  
Equation 3.4 Percentage light transmission (% Transmission) 
%Transmission = (I / I0) x 100 
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Figure 3.4 Setup of different light penetration experiments. (A) Setup for measuring light 
penetration through the head and the abdomen of a mouse. Light was aimed above the 
shaved mouse head (thickness ~7 mm) or above the opened mouse abdomen (thickness 
~10 mm). An optical sensor (diameter ~10 mm) connected to a power meter was placed 
directly under the ventral part of the brain or under the shaved abdomen of the mouse. (B) 
Picture of measuring red light penetration through the mouse abdomen. (C) INS-1E cells 
transfected with mFGFR1-CPH1So were illuminated with red light from the bottom through 
~10 mm of mouse tissue (the sides of the plates were covered with black tape). 
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3.6 Islets methods 
3.6.1 Murine islet isolation 
Pancreatic islets were isolated from 8 to 12 weeks old mice. The experimental 
animals were sacrificed by cervical dislocation. The animals were laid with the 
abdominal side facing up and sterilized with 70% ethanol and fixed with rubber 
bands on a board in order to allow the opening of the abdominal cavity with scissors 
(Figure 3.5 B). The exposed organs were placed on one side and the liver was fold 
back in order to make the common bile duct visible. The ending of the common bile 
duct into the duodenum is closed through a constrictor, sphincter of Oddi, which is 
marked by a white point. A large curved clamp was placed at the common bile duct 
close to the liver. Two additional small clamps are placed at the small intestine, in 
order to prevent the uncontrolled reflux of the collagenase solution (Figure 3.5 A). At 
the end of the common bile duct (the white point) the cannula was inserted into the 
pancreatic duct and 2 ml ice-cold collagenase solution was injected until the 
pancreas was fully bloated (Figure 3.5 C). Afterwards the clamps were removed the 
pancreas was carefully detached from the gut, stomach and spleen and put into a 
cooled 15 ml falcon. The pancreatic tissue was vortexed for 5 seconds and put into a 
shaking water bath at 37°C for 6 minutes, while vortexed every 2 minutes. The 
collagenase digest was stopped by adding 10 ml ice-cold A+AB buffer. The digested 
tissue was centrifuged for 20 seconds at 2000 rpm at 4°C. Afterwards the 
supernatant was removed and the pellet was dissolved in 12 ml of ice-cold A+AB 
buffer and again centrifuged for 20 seconds at 2000 rpm at 4°C. This whole step was 
repeated once more. The resulting pellet was resuspended in 5 ml A+AB. Further on, 
islets were selected from the cell suspension under the microscope with a 1.2 times 
magnification and transferred into a fresh petri dish containing A+AB buffer (Figure 
3.5 D and E). The selected islets were transferred twice into a fresh petri dish to 
remove remaining tissue debris (Figure 3.5 F). Finally the collected islets were 
counted and transferred into a microcentrifuge tube. After the islets were deposited 
to the bottom of the tube, the supernatant was carefully removed and murine islets 
complete culture medium was added to the islets, which were then transferred to an 
appropriate cell culture dish depending on the planed experiment. 
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Figure 3.5 Different steps of murine islets isolation and selection. (A) Illustration of the 
liver, gallbladder, the common bile duct, the sphincter of Oddi, the pancreas, the pancreatic 
duct and the duodenum. The end of the common bile duct into the duodenum is closed by 
the sphincter of Oddi, marked by a white point. Collagenase was injected through the 
sphincter of Oddi to the pancreatic duct. (B) To open the abdominal cavity and to get access 
to the duodenum, the pancreas and the common bile duct, the moues was fixed with rubber 
bands on a board. (C) To perfuse only the pancreas and to prevent the collagenase solution 
from flowing into the liver and the duodenum, a curved clamp was placed on the common 
bile duct close to the liver, and two small clamps on the duodenum on each side of the 
sphincter of Oddi. (D) Unselected cell suspension containing islets (black arrow). (E) 
Selected islets (black arrow) transferred once into a fresh dish. (F) Final select islets.  
3.6.2 Culture conditions for murine islets 
Murine islets were maintained in murine islets complete culture medium. After 
isolation murine islets were cultured overnight in complete culture medium at 37°C 
and 5% CO2 for regeneration after isolation. After ~16 hours medium was changed 
and islets were further processed for different experiments.  
3.6.3 Culture conditions for human islets 
Human adult pancreatic islets were obtained from a local collaborator (S. Kubicek, 
CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences) and 
the European Consortium for Islet Transplantation (Geneva) and the Integrated Islet 
Distribution Program (IIDP). For different experiments, islets from 4 different donors 
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with a mean age of 46 years ranging from 34 to 59 years were used. Donor details 
are given in appendix Table A4. The islet purity was ranging between 85% and 95%, 
based on reports from the islet providers. Upon their receipt, human pancreatic islets 
were maintained in human islets complete culture medium at 37°C and 5% CO2. 
Every other day medium was changed or fresh medium was added. 
3.6.4 Islets dissociation 
Murine and human islets were dissociated according to a slightly different protocol. 
All murine islets from one condition were collected in a microcentrifuge tube and 
were centrifuged for 5 minutes at 200 RCF. Medium was carefully removed and 
islets were resuspended in 150 µl trypsin/EDTA and incubated for 5 minutes at 37°C. 
After 5 minutes islets were further mechanically dissociated by repeated up and 
down pipetting. After all islets were dissociated, 1 ml of murine islets complete 
culture medium was added followed by 5 minutes centrifugation at 200 RCF. 
Supernatant was carefully removed and cell pellet was resuspended in 100 µl 
PBS/50 islets. 100 µl of cell suspension was transferred to one yellow pipette of the 
cytospin device (Figure 3.6 B). All human islets from one condition were collected in 
a 15 ml falcon tube and were centrifuge for 5 minutes at 200 RCF. Medium was 
carefully removed and the islets were resuspended in 200 µl PBS and transferred to 
a microcentrifuge tube and again centrifuged for 5 minutes at 200 RCF. Supernatant 
was removed and islets were resuspended in 25-100 µl Acutase (5000 islets/ml) and 
incubate for 20 minutes at 37°C. After 20 minutes, islets were dispersed by pipetting 
up and down 5 times, and then 1 ml of human islets complete culture medium was 
added followed by 5 minutes centrifugation at 200 RCF. Supernatant was carefully 
removed and cell pellet was resuspended in 100 µl PBS/50 islets. 100 µl of cell 
suspension was transferred to a yellow pipette tip of a cytospin device (Figure 3.6 B). 
The custom-build cytospin device145 was composed out of filter paper, a cut plastic 
tip box inlet, shortened 10 µl pipette tips, a glass slide, foldback clips and 200 µl 
pipette tips (Figure 3.6 A). The punched filter paper was placed between a glass 
slide and the cut plastic tip box inlet. Shortened 10 µl pipette tips were put in the 
holes of the filter paper and the plastic inlet. Every cell sample was applied to a 
yellow pipette tip, which was connected to the shortened 10 µl pipette tip (Figure 3.6 
B). The whole apparatus was finally placed into the plate holder of a centrifuge to 
spin down the cells onto the glass slide for 5 minutes at 750 RCF (Figure 3.6 C). 
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Figure 3.6 Custom-build cytospin device. (A -B) The cytospin was built out of filter paper, 
a cut plastic tip box inlet, shortened 10 µl pipette tips, a glass slide, foldback clips and 200 µl 
pipette tips. Yellow pipette tips were filled with cell suspension and (C) the whole apparatus 
was placed into the plate holder of a centrifuge to spin down the cells onto the glass slide. 
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3.7 Signaling detection methods 
3.7.1 PathDetect Elk1 trans-Reporting System 
Activation of the MAPK/Erk pathway was assayed with the PathDetect Elk1 trans-
Reporting System also termed luciferase assay. 5 x 104 HEK293 cells were seeded 
in 100 µl DMEM transfection medium in each well of PLO-coated 96-well clear 
bottom plates and simultaneously transfected with 210.3 ng total plasmid (0,3 ng 
receptor, 10 ng trans-activator and 200 ng trans-reporter). 6 hours after transfection, 
medium was replaced with 100 µl CO2-independent reduced serum starve medium 
supplemented with 10 µM PCB in the dark. After overnight incubation at 37°C and 
5% CO2, cells were either stimulated with red light (λ = 630 ± 5 nm, I = 6.2 µW/cm2) 
for 8 hours or protected from light at 37°C. For control experiment, cells were 
stimulated with blue (λ = 470 ± 5 nm, I = 150 µW/cm2) or green (λ = 530 ± 5 nm, I= 
6.2 µW/cm2) light instead of red light. Light intensities in an incubator equipped with 
300 light emitting diodes was controlled with a dimmer and measured with a power 
meter. After 8 hours incubation, plates were processed with Luciferase One-Glo 
Assay System according to the manufacturer’s instructions. Luminescence was 
detected with the microplate reader. 
3.7.2 Signaling activation by rtrkB/mFGFR1-CPH1So through 
synthetic tissue 
5 x 104 HEK293 cells were seeded in 100 µl DMEM transfection medium in each well 
of PLO-coated 96-well clear bottom plates and simultaneously transfected with 210.3 
ng total plasmid (0,3 ng receptor, 10 ng trans-activator and 200 ng trans-reporter). 6 
hours after transfection, medium was replaced in the dark with 100 µl CO2-
independent reduced serum starve medium supplemented with 10 µM PCB. After 
overnight incubation at 37°C and 5% CO2, the 96-well plate containing the 
transfected HEK293 cells was placed on top of the container containing the synthetic 
tissue. The two plates were taped to each other with light-impermeable tape as well 
as all transparent parts of the plates were covered with tape to ensure that cells were 
only stimulated by light that passed through synthetic tissue. Cells were stimulated 
with red light (λ = 630 ± 5 nm, I = 6.2-17.5 µW/cm2) for 8 hours at 37°C. Control cells 
were kept on the same plate but wells were fully covered with light-impermeable 
tape. After 8 hours incubation, plates were processed as described in section 3.7.1. 
3.7.3 Multi-color fluorescence reporter assay 
In order to assess MAPK/Erk pathway activation and cell viability simultaneously a 
multi-color fluorescence reporter assay was performed by using novel engineered 
fluorescence transcriptional reporters (described in section 3.3.3). For the multi-color 
fluorescence reporter assay, 5 x 104 HEK293 cells were seeded in 100 µl DMEM 
transfection medium, in each well of PLO-coated 96-well clear bottom plates. 
HEK293 cells were incubated for 16 hours at 37°C and 5% CO2, followed by 
transfection with 251 ng total plasmid (1 ng viability reporter, 100 ng transcriptional 
reporter and 150 ng receptor). Sixteen hours after transfection, medium was 
replaced with 90 µl CO2-independent reduced serum starve medium and incubated 
in the dark at 37°C at 5% CO2. After 5 hours, 10 µM PCB and, where required, 0.1 
µM Trametinib or 10% DMSO were added in the dark to each well and cells were 
49 
 
incubated for further 4 hours in the dark at 37°C at 5% CO2. Cells were then 
stimulated either with red light (λ = 630 ± 5 nm, I = 6.2 µW/cm2) or kept in the dark 
for 18 hours at 37°C. After red light illumination, medium was replaced by 50 µl PBS 
and fluorescence was measured with the microplate reader (mCerulean3: λEx/Em = 
433/475 nm, mCherry: λ Ex/Em = 588/630 nm). 
3.7.4 Immunoblotting  
3.7.4.1 Temporal precise signaling activation by rtrkB-CPH1So  
To prove the temporal precision of red-light-dependent activation of MAPK/Erk and 
PI3K/Akt pathways by rtrkB-CPH1So immunoblotting was used. 1 x 106 HEK293 
cells were seeded in 2 ml DMEM transfection medium in PLO-coated 35 mm dishes 
and simultaneously transfected with 4.02 µg total plasmid per dish (0.2 µg receptor 
and 4 µg empty vector). 6 hours after transfection, medium was replaced with 1.5 ml 
DMEM reduced serum starve medium supplemented with 10 µM PCB. After 20 
hours, cells were illuminated for 3 minutes with red light (λ = 630 ± 5 nm, I = 6.2 
µW/cm2). Cells were then either immediately, or after additional 5, 15 or 30 minutes 
in the dark washed with ice-cold PBS and lysed on ice in 250 µl RIPA buffer per dish. 
Dark control cells, control cells without PCB treatment and mock transfected cells 
were not illuminated and washed and lysed immediately. The lysates were shaken 
for 30 minutes at 4°C and centrifuged for 20 minutes at 12000 rpm at 4°C. Twenty μl 
lysate mixed with loading buffer per lane were separated by SDS-PAGE (60 minutes, 
140 V) and electro-blotted onto PVDF membranes (100 minutes, 100 V). After 1 hour 
incubation in blocking buffer at room temperature, blots were further incubated with 
primary antibodies anti phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) and anti 
Akt, or anti phosph-Akt (Ser473)(D9E) and anti Erk2 (K-23) overnight at 4°C. Primary 
antibodies were applied as a 1:1000 dilution in blocking buffer. The secondary 
antibody, goat anti rabbit IgG(H+L)-HRP conjugated, was applied at a dilution of 
1:10000 for 2 hours at room temperature. Chemiluminescence was developed with 
Clarity Western ECL Substrate and signals recorded with Molecular Imager® 
VersaDoc™MP. 
3.7.4.2 Light-dependent signaling activation in different cell lines 
To investigate signaling responses of different cell lines to visible light stimulation 
MAPK/Erk activation was assessed using immunoblotting. 1 x 106 HEK293, HeLa or 
INS-1E cells were seeded in 2 ml cell line appropriate complete medium in PLO-
coated 35 mm dishes. 16 hours after seeding medium was replaced with 1.5 ml cell 
line appropriate reduced serum starve medium. After 20 hours of starvation, cells 
were illuminated for 5 minutes with blue-green light (λ = 470 nm, I = 240 µW/cm2, λ = 
535 nm, I = 240 µW/cm2). After illumination cells were immediately washed with ice-
cold PBS and lysed on ice in 130 µl RIPA buffer per dish. Dark control cells were not 
illuminated and washed and lysed immediately. Samples were further processed as 
described in section 3.7.4.1. Blots were incubated with primary antibodies anti 
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) and anti calnexin.  
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3.7.4.3  MAPK/Erk activation in INS-1E cells through mouse abdomen by 
mFGFR1-CPH1So 
1.5 x 106 INS-1E cells were seeded in 2 ml INS-1E transfection medium in a PLO-
coated 35 mm dish that was covered with light-impermeable tape except for the 
bottom. After 16 hours of incubation at 37°C and 5% CO2 cells were transfected with 
2.5 µg total DNA per dish (0.05 µg receptor and 2.45 µg empty vector). 9.5 hours 
after transfection, medium was replaced with 1.5 ml INS-1E reduced serum starve 
medium supplemented 10 µM PCB and incubated for 18 hours in the dark. Ten mm 
of mouse tissue including shaved skin, fat, muscle, and spine was placed in a 35 mm 
dish. The dish was covered with black tape, except for a defined window (~1 cm2) at 
its bottom and top where the light could penetrate. The dish containing the cells was 
placed on top of the tissue-containing dish and were illuminated for 15 minutes with 
red light (λ = 647 ± 35 nm, I = 3.0 mW/cm2) from the bottom through the mouse 
abdomen (Figure 3.4 C). Cells were then immediately washed with ice-cold PBS, 
lysed, and processed as described in section 3.7.4.1. Dark and mock transfection 
controls as well as further steps were also performed as described in section 3.7.4.1. 
The blot was incubated with primary antibody anti phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204).  
3.7.4.4 Light-dependent signaling activation in pancreatic islets 
Immunoblots were performed to investigate downstream signaling activation in 
primary pancreatic islets upon light illumination. In particular, the activation of the 
proliferative MAPK/Erk and PI3K/Akt pathway was analyzed. 100 murine islets or 
600 human IEQ were seeded in a 60 mm dish in appropriate complete culture 
medium. After overnight incubation, islets were collected in a 15 ml falcon tube, 
centrifuged for 5 minutes at 200 rpm and resuspended in A+AB buffer. 50 murine 
islets or 300 human IEQs per condition were transferred into separate 
microcentrifuge tubes and incubated for 2 hours in the dark. After 2 hours of 
starvation in the dark islets were illuminated with blue-green light (λ = 470 nm, I = 64 
µW/cm2, λ = 535 nm, I = 64 µW/cm2) for 5 minutes followed by lysing in 30 µl ice-cold 
RIPA buffer for murine islets and 90 µl RIPA buffer for human IEQs. Dark controls 
were immediately put on ice and lysed after 2 hours of dark incubation. For an 
additional temperature control cells were wrapped in foil, to avoid light exposure, and 
placed for 5 minutes in the light incubator, followed by immediate lysis. The positive 
control was treated with 33 ng/µl FGF2 and 10% FBS for 5 minutes followed by lysis. 
Cell lysates were shaken for 30 minutes at 4°C and centrifuged for 15 minutes at 
12,000 rpm at 4°C. 30 µl of lysate mixed with loading buffer per lane were separated 
by SDS-PAGE (60 minutes, 140 V) and electro-blotted onto PVDF membranes (100 
minutes, 100 V). After 1 hour blocking at room temperature, blots were further 
incubated with primary antibodies anti phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) and anti Akt, or anti phosph-Akt (Ser473)(D9E), anti Erk2 (K-23) 
and anti vinculin overnight at 4°C. Primary antibodies were applied as a 1:1000 
dilution in blocking buffer, except anti vinculin, which was applied 1:10000. 
Secondary antibody, goat anti rabbit IgG(H+L)-HRP conjugated, was applied as 
1:10000 dilution for 2 hours at room temperature. Chemiluminescence was 
developed as described in section 3.7.4.1. 
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3.7.4.5 Wavelength- and intensity-dependent signaling activation of pancreatic 
islets 
To prove wavelength- and intensity-dependency of the light-dependent proliferative 
effect in pancreatic islets, immunoblotting was performed. In detail murine islets were 
first handled as described before in section 3.7.4.4. For wavelength-dependency the 
islets were illuminated for 5 minutes with white light and different wavelengths, blue, 
green and red (light (λ = 469 ± 35 nm, λ = 545 ± 25 nm, λ = 647 ± 70 nm, I = 64 
µW/cm2) by placing bandpass filters in front of a white LED. Blue-green illumination 
was achieved by using two LEDs (λ = 470 nm, λ = 535 nm, I = 64 µW/cm2) at the 
same time. For intensity dependency they were illuminated with blue-green light for 5 
minutes at different intensities (λ = 470 nm, λ = 535 nm, I = 0.05 µW/cm2, I = 64 
µW/cm2, I = 255 µW/cm2). Intensity was adjusted using a power meter. After 
illumination samples were further handled as described in section 3.7.4.4. 
3.7.5 Light-dependent cAMP level changes in different cell lines 
The change in cAMP levels in different cell lines (HEK293, HeLa, INS-1E) upon 
illumination was assessed using a real-time cAMP sensor (section 3.3.4). 1.5 x 104 
cells were seeded in 100 µl appropriate complete medium in each well of PLO-
coated 96-well clear bottom plate and incubated overnight at 37°C and 5% CO2. 
After overnight incubation medium was changed to 100 µl appropriate transfection 
medium and cells were transfected with 200 ng total plasmid (100 ng cAMP sensor, 
100 empty vector). 6 hours after transfection, medium was replaced by 100 µl 
Leibovitz’s L15 complete medium. Twentyfour hours after transfection, cells were 
supplemented with 10 µM 9-cis retinal in the dark and incubated overnight at 37°C 
and 5% CO2. After overnight incubation cells were supplemented with 2 mM beetle 
luciferin which was reconstituted in 10 mM HEPES and equilibrated in the dark at 
37°C followed by luminescence recording for 30 minutes every 60 seconds. 
Illumination was performed using a custom-build, external array of high-intensity 
LEDs (λ = 505 ± 15 nm, I = 9.6 mW/cm2), followed by another 15 minutes every 60 
seconds luminescence recording. Recordings were analyzed by averaging the last 
ten data points of pre-illumination and locating the maximum value after illumination.  
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3.8 Physiological methods 
3.8.1 Proliferation assay of primary pancreatic islets 
To determine an increase of proliferation in primary pancreatic islets, islets were 
illuminated for 72 hours (murine islets) or 96 hours (human islets) with blue, green 
and blue-green light (λ = 470 nm, I = 64 µW/cm2; λ = 535 nm, I = 64 µW/cm2) and 
cell proliferation was assessed by performing an nucleotide incorporation assay 
using the Click-iT® Plus EdU Alexa Fluor® 488 Imaging Kit. 25 to 50 murine islets or 
125 to 250 human IEQs per condition were cultured in either a well of a 96-well plate 
or a 35 mm dish in appropriate complete culture medium for 16 hours at 37°C in 5% 
CO2. After 16 hours, medium was changed to fresh complete culture medium 
supplemented with 5 µM EdU followed by blue-green light illumination for 72 hours or 
96 hours (the control dishes were kept in the dark). After 48 hours, 1 ml fresh 
complete culture medium supplemented with 5 µM EdU was added to each dish 
containing human IEQs. After 72 hours or 96 hours of illumination islets were 
collected and dissociated as described in section 3.6.4. Cells were fixed with 4% 
paraformaldehyde fixation solution for 8 minutes, followed by washing them three 
times with blocking buffer. Subsequently, newly synthesized DNA was stained by 
using the Click-iT® Plus EdU Alexa Fluor® 488 Imaging Kit following the 
manufacturer’s instructions. Human islets were additionally stained with an anti 
insulin antibody to determine β-cell specific proliferation and total β-cell mass. For 
anti insulin staining, cells (after nucleotide incorporation assay) were incubated for at 
least 6 hours in blocking buffer at 4°C followed by overnight incubation with the 
primary antibody (anti insulin, 1:100) at 4°C. After primary antibody incubation cells 
were washed with PBST and the secondary antibody (Alexa Fluor555 goat anti rat 
IgG, 1:200) was applied for 1 hour at room temperature. For visualizing cell nuclei, 
the slides were stained with DAPI for 5 minutes at room temperature. After washing 
with PBST, the slides were mounted with Mowiol® 4-88. Images of dispersed murine 
islets were taken with an EVOS® fluorescence microscope and images of human 
dispersed islets were taken with LSM700. Percentage of proliferation in islets was 
defined by counting total number of cells (DAPI) and proliferating cells (EdU 
positive). Percentage of insulin positive proliferating cells was defined by counting 
total number of cells and cells that were EdU positive and insulin positive. The total 
β-cell mass was defined by determining the total number of insulin positive cells in 
ratio to total cell number. 
3.8.2 Glucose-stimulated insulin secretion of human pancreatic 
islets  
To prove functionality of human islets after 96 hours, of illumination a glucose-
stimulated insulin secretion assay was performed. For every independent experiment 
at least duplicates for each condition were made and 200 to 500 human IEQs per 
condition were used. Human islets were illuminated with continuous blue-green light 
(λ = 470 nm, I = 64 µW/cm2, λ = 535 nm, I = 64 µW/cm2) and control dishes were 
kept in the dark. After 48 hours 1 ml fresh medium was added to each well 
containing. Human IEQs were collected after 96 hours of illumination and centrifuged 
for 5 minutes at 300 rpm. The supernatant was removed and human IEQs were 
resuspended in 1 ml basal buffer and transferred to a microcentrifuge tube followed 
by another 5 minutes centrifugation step at 300 rpm. The supernatant was again 
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removed and the pellet was resuspended in 500 µl basal buffer. IEQs were incubated 
for 30 minutes at 37°C in a shaking thermomixer at 300 rpm. After 30 minutes 
samples were centrifuged for 2 minutes at 300 rpm and 300 µl of the supernatant 
were collected and frozen at -80°C for further processing with the Human Insulin 
ELISA Kit. The remaining supernatant was removed and the IEQs were resuspended 
in 500 µl stimulation buffer followed by 1 hour incubation at 37°C in a shaking 
thermomixer at 300 rpm. After 1 hour the reaction was stopped by placing the tubes 
on ice followed by centrifugation for 1 minute at 300 rpm at 4°C and collection of 300 
µl of the supernatant, which was frozen at -80°C for further processing with the 
Human Insulin ELISA Kit. In order to determine the internal insulin amount, the 
remaining supernatant was removed and 500 µl of acidic ethanol was added to each 
tube and IEQs were lysed for 1 hour in an ultrasonic bath. After 1 hour samples were 
vortexed for a few seconds followed by a 5 minutes centrifugation at 300 rpm. 300 µl 
of the supernatant were collected and frozen at -80°C for further processing with the 
Human Insulin ELISA Kit. The Human Insulin ELISA was performed according to the 
manufacturer’s instructions. For normalizing insulin levels to the number of human 
IEQ, the total protein amount of each sample was determined from the cell lysate, by 
using the Pierce™ BCA Protein Assay Kit according to the manufacturer’s 
instructions.  
3.8.3 ATP quantification after blue-green light illumination in murine 
pancreatic islets 
ATP levels were determined after different time points (2 minutes, 10 minutes, and 24 
hours) of blue-green light illumination. Two hundred murine islets (100 islets per 
condition) were seeded in a 35 mm dish in murine islet complete culture medium and 
incubated overnight at 37°C and 5% CO2 in the dark. For the 2 minutes and 10 
minutes setup, islets were split in two tubes after overnight incubation and incubated 
for 2 hours in the dark before illumination. For the 24 hours setup, islets were split 
into two 35 mm dishes and were immediately illuminated after overnight incubation. 
Murine islets were illuminated with blue-green light for either 2 minutes, 10 minutes or 
24 hours (λ = 470 nm, I = 64 µW/cm2, λ = 535 nm, I = 64 µW/cm2), followed by lysis 
in 60 µl ice-cold extraction buffer. Dark controls were immediately put on ice and 
lysed. The lysates were shaken for 30 minutes at 4°C, then boiled for 3 minutes at 
95°C and finally centrifuged for 2 minutes at 20000 RCF at 4°C. ATP levels were 
determined by using the ATP Determination Kit according to the manufacturer’s 
instructions. For normalizing ATP levels to the number of islets, the total protein 
amount of each sample was determined by using the Pierce™ BCA Protein Assay Kit 
according to the manufacturer’s instructions. 
3.8.4 Light-dependent cell viability variations of different cell lines 
To assess cell viability upon illumination a MTT assay was performed. 3 x 104 cells 
were seeded in 100 µl cell line appropriate complete medium in each well of PLO-
coated 96-well clear bottom plate and incubated overnight at 37°C and 5% CO2. 
After overnight incubation medium was replaced with 100 µl cell line appropriate 
reduced serum starve medium and incubate for 24 hours at 37°C and 5% CO2 in the 
dark. After 24 hours, cells were illuminated with blue light (λ = 470 nm, I = 64 
µW/cm2) for 24 hours at 37°C and 5% CO2. Control cells were kept in the dark. After 
24 hours illumination, medium was removed and cells were incubated for 1.5 hours 
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with 0.5 mg/ml thiazolyl blue tetrazolium bromide dissolved in PBS, followed by lysis 
with 70 µl acidic isopropanol. Finally absorbance measurements were taken at 570 
nm and 690 nm in the microplate reader and cell viability was determined as 
described in section 3.4.5. 
3.9 Statistics 
Values are given as mean ± standard error of the mean (SEM) or standard deviation 
(SD), as indicated in the figure caption. Statistical significance was assessed by a 
two-tailed, paired Student’s-t test. A value of p ≤ 0.05 was considered to be 
significant. 
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CHAPTER 4: ENGINEERING AND CHARACTERIZATION OF 
RED-LIGHT-ACTIVATED RTKS  
4.1 Introduction 
The protection and regeneration of cell populations, for instance by inducing cell 
proliferation and by augmenting cell survival, is a key target in the development of 
new treatments for a variety of disorders as diabetes or Parkinson’s disease. 
Currently, very few methods are available to precisely regulate cell proliferation and 
cell survival in vivo. Growth factors are capable of activating proliferative and 
pro-survival signaling cascades, particularly the MAPK/Erk and PI3K/Akt signaling 
pathways.120,125,127,146,147 However, as described in section 1.3.2.4 the use of growth 
factors to activate their cognate receptors and subsequently proliferative and pro-
survival signaling cascades as therapeutical approach has several major limitations 
such as non-specific effects and increased risk of cancer. An optogenetic approach 
may overcome these limitations of growth factors as therapeutic agents by providing 
temporal and local activation. In a joint effort the groups of Harlad Janovjak and 
Michael Grusch have succeeded in creating optogenetic GFRs, particularly 
opto-receptor tyrosine kinases (called “Opto-RTKs”).64 Opto-RTKs were generated 
following the approach of chimeric receptor design by fusing a blue-light-sensitive 
protein domain, the LOV domain of aureochrome 1 from Vaucheria frigida to the 
kinase domain of the receptor. Moreover, the extracellular ligand-binding modules of 
RTKs were removed to obtain chimeras that are only responsive to light but not to 
native ligands (Figure 4.1 A and B). Based on these blue-light-activated Opto-RTKs, 
red-light-activated RTKs were designed and engineered (Figure 4.1 C). Red light, 
instead of blue light, as an activation signal, was chosen because red light has 
compared to blue light an increased tissue penetration that allows additional to 
temporal and spatial precise signaling activation also a non-invasive remote control 
of the system. Additionally to deep tissue penetration, red light also offers minimal 
phototoxicity and it is not overlapping with the absorbance spectrum of many 
fluorescent proteins (e.g. typical blue, green, and red fluorescent proteins are excited 
at λ ≈ 440, 490, and 560 nm, respectively). A codon optimized sensory domain of the 
cyanobacterial phytochrome 1, CPH1So, was fused to the kinase domain of the 
receptor. CPH1So was chosen as a light sensing domain because previous in vitro 
studies have shown that this N-terminal light sensing module of CPH1 
homodimerizes reversibly upon red light illumination.148  
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Figure 4.1 Structure and design of light-activated RTKs (A) RTKs consist of the 
extracellular ligand-binding domain (LBD), single-span transmembrane domain (TMD) and 
intracellular kinase domain (KD) and a C-terminal tail domain (CTD). (B) In 
blue-light-activated RTKs, only the intracellular domain is retained to generate a protein 
insensitive to its endogenous ligand. The chimeric receptor is attached to the membrane 
using a myristoylation membrane anchor (MYR) and a LOV domain is incorporated at the 
CTD to gain light sensitivity. (C) In red-light-activated RTKs, CPH1So was attached to the 
kinase domain of the receptors instead of the LOV domain.  
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4.2 Results 
4.2.1 Expression and cytotoxicity assessment of a phytochrome 
sensory domain 
Because of the homodimerizing feature of the phytochrome sensory domain, 
CPH1S, the domain was used to control protein–protein interactions in mammalian 
cells in response to red light. As CPH1S was previously never transferred to 
mammalian cells, expression in HEK293 cells, was tested and if expression would 
cause cytotoxicity in mammalian cells. CPH1S was first fused to the bright yellow 
fluorescent protein mVenus (mV), which allowed quantification of CPH1S 
expression. As a control a chemical homodimerization domain, the engineered 
FK506 binding protein (FKBP), was applied. The FKBP domain was previously 
robustly expressed in mammalian cells without measurable cytotoxicity.149 Weak 
fluorescence was observed in HEK293 cells transfected with mV-CPH1S (Figure 4.2 
A), which was indicative of poor protein expression and which may be limiting its 
further use as a red-light-sensing domain in chimeric receptors. To examine if the 
limited expression might originate from divergent codon usage of the cyanobacterial 
gene and the mammalian host cells, a codon-optimized variant of the gene 
(CPH1So) was synthesized. Indeed, CPH1So showed an increased expression in 
HEK293 cells without measurable cytotoxicity (Figure 4.2 B). Hence, CPH1So was 
further used for engineering red-light-activated RTKs.  
 
Figure 4.2 Expression and cytotoxicity assessment of a phytochrome sensory domain 
(A) Fluorescence intensity of HEK293 cells expressing CPH1S, CPH1So, and FKBP tagged 
with mV and non-transfected cells (n.t.). (B) Cell viability of HEK293 cells transfected with 
mV-FKBP or mV-CPH1So. Mean values ± SD are shown for three independent experiments 
each performed in triplicates. 
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4.2.2  Signaling activation by chimeric red-light-activated RTKs  
Two red-light-activated RTKs were created by fusing CPH1So to the C-terminus of 
mFGFR1 and rtrkB, respectively (see section 3.2.2). After engineering these two 
red-light-activated RTKs, their ability to activate certain signaling pathways, 
characteristic for RTKs, was assessed using different read-outs. 
4.2.2.1 MAPK/Erk pathway activation by red-light-activated RTKs 
The ability of red-light-activated RTKs to activate the MAPK/Erk pathway, a key 
signaling pathway of RTKs, was examined. MAPK/Erk pathway activation in HEK293 
cells expressing the chimeras, in response to red light was examined using Elk1 
trans-Reporting System. In this assay, luciferase is produced under the control of an 
engineered Elk1 transcriptional activator and pathway activation is represented as 
raw light units (RLU). HEK293 cells expressing one of the two chimeric receptors 
(mFGFR1-mCPH1So or rtrkB-CPH1So) and supplemented with PCB responded to 
dim red light with strong MAPK/Erk pathway activation (Figure 4.3). Control 
experiments showed that (i) blue as well as green light illumination of cells 
expressing mFGFR1-mCPH1So did not result in pathway activation, (ii) red light had 
no effect on cells transfected with mFGFR1-FKBP fusion protein149, and (iii) red light 
illumination of cells expressing rtrkB-CPH1So, but not supplemented with PCB, did 
not result in pathway activation (Figure 4.3). To prove kinase dependent activation of 
the MAPK/Erk pathway by red-light-activated RTKs, kinase activity was eliminated 
by introducing specific point mutations in each chimera. Y271F and Y272F mutations 
were introduced in mFGFR1-CPH1So and a K131A mutation was introduced in 
rtrkB-CPH1So.150,151 In both chimeras these mutations abolished the 
red-light-dependent signaling activity, proving the kinase dependent signaling 
activation by red-light-activated RTKs (Figure 4.3). Finally, substituting R195 with 
glutamic acid in mFGFR1-CPH1So, which prevents the formation of a functionally 
essential, asymmetric kinase domain dimer in mFGFR1152, abolished pathway 
activation (Figure 4.3), indicating that receptor dimerization is also required for 
receptor activation by CPH1So. 
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Figure 4.3 Activation of the MAPK/Erk pathway by mFGFR1-CPH1So and rtrkB-
CPH1So in response to red light. Additional control experiments for mFGFR1-CPH1So 
show MAPK/Erk pathway activation upon green or blue light illumination or after the 
introduction of different mutations to mFGFR1-CPH1So (Y271F/Y272F and R195E). Control 
experiments for rtrkB-CPH1So sow MAPK/Erk pathway activation after the introduction of a 
point mutation (K131A) and without the supplementation of PCB. No MAPK/Erk activation 
was detected upon red light illumination in cells expressing mFGFR1-FKBP. MAPK/Erk 
pathway activation is expressed as RLU in HEK293 cells. Mean values ± SEM for technical 
replicates of 2–17 independent experiments, each performed in triplicate, are shown. Except 
“No PCB”, mean value ± SEM for three technical replicates of one independent experiment 
is shown. Light intensity: 6.2 µW/cm2 (red and green), 150 µW/cm2 (blue); duration of 
illumination: 8 hours 
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4.2.2.2 Temporal precise signaling activation by rtrkB-CPH1So 
To prove additionally to the signaling functionality also the ability of rtrkB-CPH1So to 
control signalling with high temporal precision, a time course experiment in HEK293 
was performed. In this experiment the phosphorylation levels of Erk and Akt upon 
red light illumination were determined by immunoblotting in a time-dependent 
manner. The results demonstrated that 3 minutes of red light illumination were 
sufficient for activating the MAPK/Erk and PI3K/Akt pathways, detected as increased 
levels of phosphorylated Erk and Akt. After termination of the red light illumination, 
pErk levels returned to basal levels after 30 minutes, and pAkt levels already after 15 
minutes (Figure 4.4). Overall, these results demonstrated that rtrkB-CPH1So allowed 
the activation of key intracellular signaling pathways with a high temporal resolution 
and in a reversible manner in response to red light. 
 
Figure 4.4 Time-dependent phosphorylation of Erk (pErk) and Akt (pAkt) in HEK293 
cells transfected with rtrkB-CPH1So. Cells were illuminated for 3 minutes with red light (λ 
630 ± 5 nm) followed by indicated duration (minutes) of darkness. Light intensity: 6.2 
µW/cm2 
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4.2.3 Activation of red-light-activated RTKs through various tissues 
4.2.3.1 MAPK/Erk pathway activation through synthetic tissue 
An important feature of red light is its ability to penetrate tissue more deeply than 
blue or green light.143 To validate the ability of red-light-activated RTKs to be 
activated non-invasively through mammalian tissues, synthetic tissues mimicking the 
absorption spectrum of different mammalian tissue, such as muscle, skin and skull 
were generated by spiking agarose gels with different organic chemical dyes and 
comparing the absorption spectrum to published spectrums (Figure 4.5 A-C). 
HEK293 cells transfected with one of the two chimeric receptors (mFGFR1-CPH1So 
or rtrkB–CPH1So) were then stimulated through synthetic muscle, skin, and skull or 
combinations of two different synthetic tissues. Activation of the receptors was 
assessed by MAPK/Erk pathway activation using an Elk1 trans-Reporting System. 
Red light illumination through various synthetic tissues and combinations of synthetic 
tissues resulted in a potent induction of MAPK/Erk signaling (Figure 4.5 D and E). 
These results were the first indication that red-light-activated RTKs may allow non-
invasive signaling activation in vivo. 
 
Figure 4.5 Absorption properties of synthetic tissues and MAPK/Erk pathway 
activation through synthetic tissues. (A-B) Absorption properties of mammalian 10 mm 
muscle (A), 0.5 mm skin (B) and 10 mm skull (C) (circles; data taken from literature)142-144 
and of the corresponding synthetic tissues produced by spiking agarose gel with various 
dyes (squares). (D-E) Activation of MAPK/Erk pathway in HEK293 cells transfected with 
mFGFR1-CPH1So (D) or rtrkB-CPH1So (E) illuminated through synthetic tissues mimicking 
10 mm muscle, 0.5 mm skin, 3 mm skull, a combination of 0.5 mm skin and 10 mm muscle 
and a combination of 0.5 mm skin and 1.5 mm skull. Mean values ± SEM for one to three 
independent experiments performed in triplicates are shown. Light intensity: 6.2-
17.5 µW/cm2; duration of illumination: 8 hours 
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4.2.3.2 MAPK/Erk pathway activation in INS-1E cells through mouse 
abdomen 
Synthetic tissues were mimicking the absorption, but not scattering properties of 
mammalian tissues.153 Therefore an additional experiment using real mouse 
abdomen was performed. In initial experiments, the deeper tissue penetration of red 
light compared to other wavelength was verified by a light transmission experiment 
with blue, green and red light in mouse abdomen and skull. The results 
demonstrated that ~0.034% of red light penetrates through one centimeter of mouse 
abdomen and ~0.44% through 0.67 centimeter of the mouse head, whereas blue 
showed and penetration of around 0.004% through mouse abdomen and 0.002% 
through mouse head and green light less than 0.001% transmission through mouse 
abdomen and almost no transmission through mouse head (Figure 4.6 A and 
B).These results proved that red light had more than a 8 fold higher transmission 
through mouse abdomen and more than 220 fold higher penetration rate through 
mouse head than blue and green light. Based on this experimentally determined 
transmission of blue, green and red light through one centimeter of mouse abdomen 
and referring to the Kubleka-Munk theory (Equation 4.1), the transmitted light 
intensity through different depths of mouse abdomen was calculated (Equation 4.2). 
As an input intensity 5 W/cm2 was chosen as this is representative for maximum 
intensities used in photodynamic therapy.154 As presented in Figure 4.6 (C) the 
required light intensity of ~6 µW/cm2 of red light to activate red-light-activated RTKs 
can be achieved up to a depth of 1.8 centimeter by applying a maximum input power 
of 5 W/cm2. In contrast blue-light-activated RTKs can only be activated up to a tissue 
thickness of one centimeter due to the reduced tissue penetration of blue light and 
the increased activation intensity needed by blue-light-activated RTKs. These results 
indicated the possibility of activating red-light-activated RTKs transdermally without 
the need of an implant in mice. 
Equation 4.1 Kubelka-Munk theory155 
Transmittance (T) = exp [-(K2 + 2KS)1/2 d] 
where K is the absorption coeffcient(cm-1), S is the scattering coefficient (cm-1) and d is depth from the surface 
(cm) 
Equation 4.2 Output intensity through mouse abdomen 
Output intensity (µW/cm2) = T(experimentally determined)Depth x input intensity 
(µW/cm2) 
To validate this prediction, INS-1E cells were transfected with mFGFR1-CPH1So, 
illuminated with red light through one centimeter of mouse abdomen and MAPK/Erk 
activation was assessed by immunoblotting. INS-1E cells are an insulinoma cell line; 
they are frequently used in studies of pancreatic β-cell also in the context of 
diabetes.141 INS-1E cells were chosen as a model system for this experiment 
because it was previously shown that decreased FGF signaling contributes to 
diabetes and that FGF signaling improves β-cell function in diabetic mice.121,126 
Furthermore β-cells (located in the pancreas) are located ~0.5 – 1 centimeter away 
from the mouse skin. We found that the MAPK/Erk pathway can be activated in INS-
1E cells transfect with mFGFR1-CPH1So by red light illumination through ~1 
centimeter of mouse abdomen (Figure 4.6 D). Notably, the applied light intensity (I = 
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3.0 mW/cm2) was easily attained with standard light emitting diodes and were even 
lower than those used in photodynamic therapy154, demonstrating the ability of non-
invasive activation of red-light-activated RTK through mammalian tissue. 
 
Figure 4.6 Light penetration and MAPK/Erk activation in INS-1E cells through mouse 
tissue. (A and B) Light penetration measurements of blue (470nm), green (545nm) and red 
(640nm) light through one centimeter of mouse abdomen (A) and 0.67 centimeter of intact 
mouse head (B). Percentages of transmitted light are presented. Error bars represent ± 
SEM. (C) Calculated transmitted light intensities (µW/cm2) of red, blue and green light 
through different depths of moues abdomen. The applied input intensity was 5 W/cm2. 
Dashed lines indicate minimal intensity need to activate Opto-RTKs (blue; 150 µW/cm2) or 
red-light-activated RTKs (red; 6 µW/cm2). (D) MAPK/Erk activation indicated by pErk levels 
in INS-1E cells transfected with mFGFR1-CPH1So and stimulated through one centimeter of 
mouse tissue with red light (λ = 647 ± 35 nm). Light intensity: 3 mW/cm2; duration of 
illumination: 15 minutes  
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4.3 Discussion 
There is a consensus in the field of regenerative medicine that a tightly spatial and 
temporal controlled growth factor signaling would be an efficient approach for tissue 
regeneration in diseases as diabetes.135 Because light displays three major 
advantages over conventional pharmacological means as high temporal and spatial 
resolution and the possibility of remote application, light is the perfect stimulus for 
activating growth factor signals. The engineering of red-light-activated RTKs, which 
are activated with a wavelength of 630 nm, can overcome the drawback of 
blue-light-activated receptors that would also be candidates for light-dependent 
restoration, their limited tissue penetration, which is resulting in the use of invasive 
implants or powerful light sources.129,130 The increased tissue penetration of red light 
over blue and green light was verified by a light penetration experiment through 
mouse abdomen and head (Figure 4.6). To achieve red light control of growth factor 
signaling, the sensory domain of phytochrome CPH1 was chosen as a 
red-light-sensing domain, because it was shown by in vitro assays that the sensory 
module of CPH1 undergoes light-dependent changes into a dimerization state.148 
First expression experiments showed that a mammalian codon optimization was 
necessary to increase protein expression to an acceptable level. In the past, several 
studies have already shown that modifying the coding sequence of a gene is an 
expedient way to increase protein expression, because it is known that the choice of 
synonymous codons in many species is strongly biased and that there is a 
correlation between high protein expression and the use of certain codons in a 
specific organism.156,157 Efficient expression of codon-optimized genes can be 
related not only to the abundance of isoacceptor tRNAs in a specific organism, but 
also to the formation of a favorable secondary structure of the transcripts for 
translation. Hence, mammalian codon optimization can result in stable mRNA 
secondary structures because of stronger GC base pairing.156,158 The mammalian 
codon-optimized version of CPH1S further allowed the engineering of 
red-light-activated RTKs. It was shown that red-light-activated RTKs are able to 
activate major growth factor signaling pathways with high temporal resolution, which 
cannot be achieved by growth factors or chemical activators.135,149 Additionally the 
ability of red light to penetrate through different synthetic tissues and one centimeter 
of real mouse tissue, in order to activate red-light-activated RTKs and subsequently 
the MAPK/Erk pathway, was demonstrated. It was additionally proven that 
red-light-activated RTKs enable light-activated signaling in situ without invasive 
implants. These results verified that red-light-activated RTKs may be a very 
attractive tool for light-controlled cellular signaling in vivo, especially due to the 
potential for precise signaling activation to ensure a save application without side 
effects due to prolonged and systemic activation. Nevertheless red-light-activated 
RTKs also have to deal with some potential drawbacks, in particular for its translation 
into humans. Although it was proven that red light penetrates deep enough to 
activate red-light-activated RTKs remotely in mouse abdomen and head, for 
therapeutical applications in humans the tissue penetration of red light is probably 
not sufficient for applications deeper than subcutaneous layers. Light transmittance 
is affect by both the thickness and the optical properties of human tissue. The optical 
properties such as absorption and scattering depend on the composition of the 
tissue and are distinct, for instance, for skin, muscle, fat or bone.143 In order to 
present the relevant factors for transmittance, according to previous studies, it can 
be roughly considered that a human body wall is composed of absorbing and 
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scattering particles and the Kubelka-Munk theory can be applied to estimate its 
optical properties.143,155 The different levels of light transmittance through head and 
abdomen can be explained by the different optical properties based on different 
tissue composition. While abdominal tissue includes skin, blood, fat and muscle, the 
head is composed mainly out of skin skull and brain (Figure 4.6 A and B). The 
transmittance at a certain wavelength decreases exponentially with an increase in 
depth, based on this fact the transmitted light intensity transmitted through different 
depths of mouse abdomen was calculated (Figure 4.6 C). Based on these 
calculations it can be stated that red-light-activated RTKs can be controlled remotely 
in mice, but they are not suitable for an implant-free therapeutical approach in 
humans for disease like diabetes or Parkinson’s disease as not enough light is 
reaching the tissue of interest.143  
A contentious point of red-light-activated RTKs is the essential administration of the 
chromophore PCB to mice and humans. PCB is necessary for the ability of CPH1S 
to sense light, but mice as well as humans are lacking this chromophore. PCB is 
structurally closely related to the human bile pigments biliverdin and bilirubin.159 
Bilirubin is one of the most potent endogenous antioxidant substrates.160 In relation 
to this characteristic of PCB, previous studies showed several positive effects of 
PCB relating to atheroprotection, liver regeneration and diabetic neuropathy.160-162 
PCB from Spirulina can be orally administrated to mice. Because Spirulina is used 
as a nutritional supplement for human and animals in many countries, as natural dye 
in cosmetics as well as supplement in pharmaceutical productions, it may be feasible 
to produce commercial quantities of PCB for human administration.162 By assuming 
that humans and rodents digest and absorb Spirulina-bound PCB in a comparable 
manner, it can be concluded that an intake of 2 heaping tablespoons daily would be 
likely to have antioxidant activity in humans, but it is not known how much intake 
would be sufficient for red-light-activated RTKs.159 Because a possible future 
application of red-light-activated RTK could be the regeneration of pancreatic β-cells, 
the positive effect of PCB on diabetic neuropathy is an attractive aspect and would 
allow a therapeutic approach against diabetes focusing on both the causal event 
(loss of functional β-cells) as well as a secondary disease (neuropathy) 
simultaneously. However, the necessity of PCB administration are on the one hand 
very favorable because of its additional positive antioxidant effect and it is ease to 
administer, on the other hand the routinely regular administration of PCB in human is 
not yet studied in detail and the assumptions on positive effects are based on animal 
studies. To exclude any severe side effects due to long-term PCB administration or 
incorrect dosage further animal studies as well as clinical studies are necessary to 
guarantee safety. 
Additional to the required light implant and the administration of PCB for a 
therapeutical use in humans, red-light-activated RTKs also entail the necessity of 
gene therapy. Gene therapy is a fascinating and innovative technology due to its 
potential to treat diseases at their genetic roots.131,163,164 In gene therapy a 
malfunctioning gene is counteracted or replaced within the adversely affected cells. 
As simple as the concept of gene therapy sounds, the manner to put it into practice 
is quite challenging. To deliver new genetic information to target cells, complex 
cellular and tissue barriers have to be overcome without disrupting essential cellular 
regulatory mechanisms.132 In the last 25 years, remarkable progress has been made 
and a number of gene therapy applications have provided benefit to patients in 
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clinical trials. For example the successful transduction of bone marrow stem cells 
with lentiviral vectors to treat early-onset metachromatic leukodystrophy as well as 
the successful treatment of patients with inherited retinopathies and hemophilia B by 
local or systemic injection of adenovirus-associated viral vectors.131,163-165 
Nevertheless every now and then severe side effects occur after viral based gene 
therapy as the development of leukemia after treating severe combined immune 
deficiency patients with murine leukemia virus gene delivery vectors.131 Although 
there are promising numbers of successful gene therapy approaches there are 
remaining challenges in providing a quantitative prediction of actual oncogenic risk in 
clinical setting as well as further improvements in safety, efficacy and manufacturing 
of gene delivery vectors are still required.131,132 Therefore the option to apply 
red-light-activated RTKs to regenerate disease affected cells as in diabetes or other 
degenerative disease is of course an option, but probably also because of the 
necessity of a light implant and PCB administration, a last therapeutical approach 
and not as a state of the art therapy. 
However, red-light-activated RTKs are attractive for optogenetic applications in 
animal models, given that red light offers deeper tissue penetration than other 
wavelengths, transdermal control and the fact that PCB can be easily orally 
administered. Gene deliveries via lentiviral vectors or adeno–associated viral vectors 
in mice are well-established methods.101,102,166 Red-light-activated RTKs are an 
innovative tool for studying the spatial and temporal involvement of growth factor 
signaling events in degenerative disease, but also for developmental and behavioral 
studies. In developmental research a key aspect is the manipulation of cellular 
signaling processes, to understand the complex and acutely orchestrated signaling 
cascades of multiple interacting pathways that finally give rise to complex tissues 
and organs. Traditional methods are often limited to understand these temporal and 
spatial coordinated signaling events because of less specificity or lethality of full 
knockouts. By now methods to completely silence signals are well established, but 
applying signal control with high spatial and temporal precision is still challenging. 
Light-controlled tools can help to unravel these complex mechanisms due to their 
unprecedented precise control, allowing the investigation of specific cell types or 
signaling pathways and their local and temporal regulation during development.65,167 
Moreover the field of behavioral research, also in combination with degenerative 
disorders as Parkinson’s disease, is an attractive field for applying red-light-activated 
RTKs, because no implants are needed for receptor activation a higher throughput of 
animals is enabled and animals are not influenced and disabled by additional 
hardware. Remote receptor control allows free moving and normal behavior of the 
animals during the study, which will lead to more robust and reliable outcomes of 
behavioral studies. Because of all these facts red-light-activated RTKs probably will 
not be the first choice of treatment for degenerative diseases, but a very attractive 
tool for a broad variation of research fields.  
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CHAPTER 5: LIGHT INDUCED β-CELL PROLIFERATION 
5.1 Introduction 
Optogenetic tools can only be used as therapeutic agents by using gene therapy, 
which is accompanied by risk factors that are difficult to predict such as described in 
section 4.3. Therefore, a new light-based strategy was investigated, that does not 
require gene transfer, to achieve promotion of cell proliferation and increase of cell 
survival, the key goal in the treatment of various diseases. As model cells, murine 
and human pancreatic islets/β-cells were used, since the lack of functional β-cells is 
the main cause of diabetes mellitus, induced by various genetic and environmental 
factors. This new light-based approach does not require gene transfer, it has the 
potential to be fully reversible, unlike in the case of conventional optogenetics and 
growth factor therapy, and in contrast to pharmacological approaches, offers tissue 
specificity. As it will be described in the following chapter, it is based on endogenous 
light-sensitive mechanisms, which lead to the activation of proliferative and 
pro-survival cellular signaling mechanisms.  
Various studies in a broad spectrum of research fields have already investigated the 
influence of visible light on cell behavior. For example, Buscone and colleagues 
showed that rhodopsin as well as OPN3 is expressed in human hair follicle cells and 
that blue light illumination exerts a positive effect on their growth ex vivo, this effect 
could be reduced after silencing OPN3 by siRNA transfection, indicating the 
potentially involvement of OPN3 in this effect.168 Another study showed that green 
light illumination directed the migration of human orbital fat stem cells (OFSC) 
through the activation of the MAPK/Erk/p38 signaling pathway. In this study, it was 
hypothesized, based on gene expression analysis, that the retinal pigment 
epithelium-derived rhodopsin homolog and also OPN3 are responsible for the 
green-light-induced OFSC migration.169 In chicken embryos, it was demonstrated 
that in ovo illumination with green light resulted in enhanced body and muscle 
weight, a significant increase in the number of skeletal muscle cells as well as an 
enhanced number of proliferating cells in the intact muscle.170 In addition to these 
blue- and green-light-based studies, there is also an extensive number of studies 
that investigate the positive effect of red and near-infrared light on cell behavior in 
various cell and disease models, ranging from neurodegenerative disorders, over 
wound healing to skeletal muscle regeneration.171 For instance, several studies 
showed the therapeutic effect of red and near-infrared light on MPTP- and 
MPP+ -induced Parkinson’s disease models.172,173 There is now a growing 
consensus that red and near-infrared light is acting on cells through cytochrome c 
oxidase (CcO), as primary photoacceptor. CcO is the terminal enzyme of the 
mitochondrial electron transport chain, mediating the transfer of electrons from 
cytochrome c to molecular oxygen.171,174 CcO has an absorption maximum around 
430 nm and a secondary peak the red/near-infrared wavelength range.175 Absorption 
of light by CcO can increase the levels of ATP and reactive oxygen species, leading 
to enhanced energy availability and signal transduction.171,174 Although in some of 
these studies, the detailed molecular mechanisms of the light-induced cellular effects 
were partially unraveled, in many cases they are still unresolved.  
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5.2 Results 
5.2.1 Characterization of light-induced cell behavioral effects 
5.2.1.1 Light-induced proliferation of murine and human islet cells 
The influence of visible light on islet cell proliferation was determined by a nucleotide 
incorporation assay. Murine islets were illuminated with different wavelengths of 
visible light (blue: λ = 470 nm, green: λ = 535 nm, blue-green: λ = 470 nm and λ = 
535 nm) to determine light dependent proliferative effects. Blue or green light alone 
was not sufficient to increase proliferation in murine islets (Figure 5.1 A and B), but 
the combination of blue and green light (blue-green light) led to a significant increase 
in proliferation in murine islets after 72 hours of illumination (Figure 5.1 C). 96 hours 
of combined blue-green light illumination also led to a significant increase in 
proliferation in human islets (Figure 5.1 D). Except for two outliers in the human data 
set, murine islets showed a higher level of basal proliferation with around 2%, 
compared to human islets with an average basal proliferation of less than 1% 
(excluding the two outliers that exhibited high levels of proliferation in the dark). 
However, human islets as well as mouse islets showed a very reproducible increase 
in proliferation upon blue-green light illumination (1.6- and 1.4-fold, respectively). 
 
Figure 5.1 Light-induced proliferation of murine (A-C) and human (D) islet cells. (A) 
Murine islets: Percentage of proliferative cells upon blue light illumination, compared to non-
illuminated cells (Dark). Individual experimental values (grey, blue) and mean (black) ± SEM 
are shown for six independent experiments (light intensity: 14 µW/cm2; duration of 
illumination: 72 hours). (B) Murine islets: Percentage of proliferative cells upon green light 
illumination, compared to non-illuminated cells. Individual experimental values (grey, green) 
and mean (black) ± SEM are shown for three independent experiments (light intensity: 
14 µW/cm2; duration of illumination: 72 hours). (C) Murine islets: Percentage of proliferative 
cells upon blue-green (BG) light illumination, compared to non-illuminated cells. Individual 
experimental values (grey, blue-green) and mean (black) ± SEM are shown for ten 
independent experiments (light intensity: 14 µW/cm2 each wavelength; duration of 
illumination: 72 hours). (D) Human islets: Percentage of proliferative cells upon BG light 
illumination, compared to non-illuminated cells. Individual experimental values (grey, 
blue-green) and mean (black) ± SEM are shown for seven independent experiments (light 
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intensity: 64 µW/cm2 each wavelength; duration of illumination: 96 hours) (A-D) two-tailed, 
paired Student’s t–test, a value of p ≤ 0.05 was considered to be significant (*p ≤ 0.05, **p ≤ 
0.01, n.s.: not significant) 
5.2.1.2 Influence of blue-green light on β-cell specific proliferation and total 
β-cell mass in human islets 
The β-cell specificity of the proliferative effect as well as the influence of illumination 
on total β-cell mass was determined by anti-insulin antibody staining. Because the 
percentage of β-cells in murine islets is up to 80%, no specific analysis of β-cells was 
performed in the mouse tissue. As human islets are more heterogeneous in regard 
to cell type distribution than murine islets, it was investigated whether the 
proliferative effect in human islets is β-cell specific. A very clear trend of increased 
β-cells proliferation upon blue-green light illumination can be observed. The results 
are not significant due to the inclusion of one dataset that shows an extreme 
increase in proliferation. In the dark, 0.5% of all cells are proliferative β-cells (~27% 
of all proliferative cells), whereas 96 hours of blue-green light illumination led to an 
almost 4 fold increase of proliferative β-cells (Figure 5.2 A), proving that at least a 
substantial part of the light induced proliferation is β-cells specific (~40% of all 
proliferative cells). Shown previously, proliferative agents often displayed 
concomitant de-differentiating effects,103,176 therefore the overall composition of 
illuminated islets was monitored by determining the total number of β-cells. Insulin 
staining revealed no reduction, but rather a small overall increase of the total β-cell 
mass after illumination (Figure 5.2 B), indicating that blue-green light illumination of 
96 hours did not induce any de-differentiation. 
 
Figure 5.2 Determination of β-cell specific proliferation and total β-cell mass in human 
islets. (A) Percentage of insulin positive (+) proliferative cells after BG light illumination, 
compared to non-illuminated cells. Individual experimental values (grey, blue-green) and 
mean (black) ± SEM are shown for five independent experiments. (B) Percentage of total 
insulin+ cells after BG light illumination, compared to non-illuminated cells. Individual 
experimental values (grey, blue-green) and mean (black) ± SEM are shown for five 
independent experiments. (A-B) Light intensity: 64 µW/cm2 each wavelength; duration of 
illumination: 96 hours; two-tailed, paired Student’s t–test, a value of p ≤ 0.05 was considered 
to be significant (n.s.: not significant) 
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5.2.1.3 Preserved islet functionality upon blue-green light illumination 
To investigate the effect of prolonged illumination on islet functionality, in particular 
on their ability to secrete insulin in response to high glucose, a glucose-stimulated 
insulin secretion assay was performed. After 96 hours of blue-green light 
illumination, basal insulin secretion (3.3 mM glucose) as well as high glucose (16.7 
mM glucose) stimulated insulin secretion of human islets was assessed. While donor 
to donor variability of the overall insulin secretion ability was observed, blue-green 
light illumination did not have a negative effect on islet functionality. On the contrary, 
blue-green light illumination rather led to an increase of islet insulin secretion 
potential. While blue-green light illumination had no or only a small effect on insulin 
secretion under basal glucose conditions, islets from two donors (donor 1 and donor 
3) secreted more insulin after illumination compared to untreated islets, when 
challenged with high-glucose (Figure 5.3 A). Moreover, the amount of intracellular 
insulin was investigated to evaluate for conserved β-cell properties after illumination. 
Except for donor 3, blue-green light illuminated human islets contained similar 
amounts of intracellular insulin compared to untreated islets from the same donor, 
further demonstrating that blue-green light illumination had no negative effect on 
β-cell properties (Figure 5.3 B). The unexpected high intracellular insulin level of the 
untreated sample of donor 3 arises from one outlier of the sample replicates and is 
therefore not a representative data point.  
 
Figure 5.3 Influence of blue-green light illumination on insulin secretion (A) and 
internal insulin levels (B) in human islets (A) Measurement of glucose-stimulated insulin 
secretion in human islets kept in the dark or illuminated with blue-green light. Secreted 
insulin values were normalized to total protein amount of each sample. (B) Measurement of 
internal insulin of human islets kept in the dark or illuminated with blue-green light. Secreted 
insulin values were normalized to total protein amount of each sample. (A-B) Light intensity: 
64 µW/cm2; duration of illumination: 96 hours; values were assessed in two (donor 1 and 3) 
or four replicates (donor 4) for each donor and mean values ± SEM are shown. 
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5.2.2 Signaling activation in murine and human islets cells 
5.2.2.1 MAPK/Erk signaling activation in murine and human islets 
The MAPK/Erk pathway was previously associated with positive proliferative effects 
in pancreatic islets and β-cells, which can for example be activated by various 
growth factors.120,126,177,178 The ability of blue-green light illumination to activate the 
pro-proliferative MAPK/Erk pathway was assessed by determining the levels of pErk 
by immunoblotting. Five minutes of illumination was sufficient to activate the 
MAPK/Erk pathway, both in murine (Figure 5.4 A and C) and human islets (Figure 
5.4 B and D). pErk levels were increased by a factor of 2.5 in murine islets and a 
factor of 2.3 in human islets after light treatment. As a positive control the fibroblast 
growth factor 2 (FGF2) combined with 10% FBS, acting on multiple GFRs, was used. 
Previous studies have proven the ability of FGFs to activate the MAPK/Erk pathway 
in β-cells, as well as their significant role in β-cell function.121,122,126  
 
Figure 5.4 MAPK/Erk signaling activation in murine (A, C) and human islets (B, D). (A) 
Murine islets: Quantification of blue-green-(BG) light-induced pErk increase from 
immunoblott analysis. Mean values ± SEM are shown for four independent experiments. (B) 
Human islets: Quantification of BG-light-induced pErk increase from immunoblott analysis. 
+Ctr: positive control stimulation with 10% FBS and 33 ng/ml FGF2. Mean values ± SEM are 
shown for three independent experiments. (C) Murine islets: Representative immunoblot of 
BG-light-induced pErk increase. (D) Human islets: Representative immunoblot of BG-light-
induced pErk increase. (C-D) Loading Ctr: (C) total Akt or (D) vinculin; light intensity: 64 
µW/cm2; duration of illumination: 5 minutes 
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5.2.2.2 PI3K/Akt signaling activation in murine and human islets 
The PI3K/Akt pathway was previously associated with pro-survival effects in 
pancreatic islets and β-cells, which can be activated, similar to the MAPK/Erk 
pathway, by various growth factors.120,126,177,178 The ability of blue-green light 
illumination to activate the pro-survival PI3K/Akt pathway was assessed by 
determining the levels of pAkt by immunoblotting. Again, 5 minutes of illumination 
was sufficient to activate the PI3K/Akt pathway, both in murine (Figure 5.5 A and C) 
and human islets (Figure 5.5 B and D). pAkt levels were increased by a factor of ~2 
in murine and human islets. FGF2 combined with 10% FBS was again used as a 
positive control for pathway activation.122,126 The level of pAkt increase upon 
blue-green light in human islets was comparable with that of the positive control 
(Figure 5.5 B and D).  
 
Figure 5.5 PI3K/Akt signaling activation in murine (A, C) and human islets (B, D) (A) 
Murine islets: Quantification of BG-light-induced pAkt increase from immunoblott analysis. 
Mean values ± SEM are shown for two independent experiments. (B) Human islets: 
Quantification of BG-light-induced pAkt increase from immunoblott analysis. +Ctr: positive 
control stimulation with 10% FBS and 33 ng/ml FGF2. Mean values ± SEM are shown for 
three independent experiments. (C) Murine islets: Representative immunoblot of BG-light-
induced pAkt increase. (D) Human islets: Representative immunoblot of BG-light-induced 
pAkt increase. (C-D) Loading Ctr: (C) vinculin or (D) total Erk; light intensity: 64 µW/cm2; 
duration of illumination: 5 minutes 
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5.2.3 Characterization of the endogenous light-sensing mechanism 
5.2.3.1 Wavelength dependency of MAPK/Erk activation by visible light 
To determine the wavelength dependency of the light-based effects in murine islets, 
MAPK/Erk pathway activation upon illumination with different wavelengths (blue: λ = 
469/35 nm, green: 545/25 nm, red 647/70nm, blue-green: λ = 470 nm and λ = 535 
nm, white: λ = 400-700 nm) was assessed by immunoblotting. Five minutes of 
illumination with a combination of blue-green light as well as with green light alone 
resulted in increased phosphorylation of Erk, whereas blue or red light alone did not 
elicit any signaling activation (Figure 5.6). As expected, white light, which includes 
light of the whole wavelength spectrum of visible light, also activated the MAPK/Erk 
pathway in murine islets. 
 
Figure 5.6 Influence of wavelength on light-dependent MAPK/Erk pathway activation 
in murine islets. Quantification of pErk levels in murine islets assessed by immunoblotting. 
Light intensity: 64 µW/cm2 each wavelength; duration of illumination: five minutes; mean 
values ± SEM are shown for three to four independent experiments.  
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5.2.3.2 Intensity dependency of MAPK/Erk activation by blue-green light 
To investigate how these observed effects depend on light intensity, MAPK/Erk 
pathway activation upon illumination with different intensities of blue-green light was 
assessed by immunoblotting. Comparable levels of MAPK/Erk pathway activation 
over a wide range of intensities from 0.5 µW/cm2 to 255 µW/cm2 blue-green light was 
determined (Figure 5.7), indicating a very robust and light-sensitive mechanism.  
  
Figure 5.7 Influence of light intensity on BG-light-dependent MAPK/Erk pathway 
activation in murine islets. Quantification of pErk levels in murine islets assessed by 
immunoblotting after five minutes illumination with different light intensities of blue-green 
light. Mean values ± SEM are shown for three to four independent experiments.  
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5.2.3.3 Alternative protocol for dark samples 
To exclude that the observed light-based effects occur due to different sample 
handling, which results in different sample environment such as temperature 
differences, control immunoblot experiments were performed. In this control 
experiment, an additional dark control was included, which was protected from light 
by foil and placed for the same time period in the light incubator as the light sample. 
This procedure differed from the “standard” immunoblott procedure, where the dark 
control was put immediately on ice and lysed. In addition temperature was manually 
verified during the whole incubation period. There was no increased MAPK/Erk 
pathway activation in the dark sample placed in the light incubator (Dark(i)), 
compared to the original dark control (Figure 5.8 A and B), indicating that MAPK/Erk 
signaling activation is due to illumination with blue-green light and not due to 
temperature changes resulting from illumination. 
 
Figure 5.8 MAPK/Erk pathway activation in murine islets including an alternative dark 
control, to exclude environmental influences due to handling differences. (A) 
Quantification of pErk levels in murine islets assessed by immunoblotting. Mean values ± 
SEM are shown for two independent experiments. (B) Representative immunoblot of 
temperature control experiments. Loading Ctr: vinculin; light intensity: 64 µW/cm2; duration 
of illumination: 5 minutes 
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5.2.3.4 Opsin expression in murine and human islets 
To identify opsins expressed in murine and human islets, reverse transcribed cDNA 
from isolated islet RNA was analyzed by PCR. Insulin as well as β-actin was used as 
a positive control for RT-PCR, because they are expressed in β-cells. As an 
additional control a –RT (no added reverse transcriptase) control was introduced to 
exclude any genomic DNA (gNDA) contamination. Opsin expression was always 
verified with two primer sets for every specific opsin (Table A3), which were quality 
tested using gDNA (not shown). Each RT-PCR product was assessed by gel 
electrophoresis as well as sequencing. Some of the PCR products, such as for 
murine OPN1WM and Melanopsin, resulted from mispriming, as determined by 
sequencing, and did not indicate actual opsin expression (Figure 5.9, Table 5.1). 
Two opsins, OPN3 and rhodopsin, were expressed in both, murine and human islets. 
OPN3 showed intense bands and its expression was also verified by sequencing 
analysis (Figure 5.9, Figure 5.10, Table 5.1). Rhodopsin was expressed at lower 
levels, but also in both, human and murine islets (Figure 5.9, Figure 5.10, Table 5.1). 
Due to these results, it was hypothesized that OPN3, rhodopsin or a combination of 
both could be responsible for the blue-green-light-induced effects in pancreatic islets. 
This hypothesis is also coinciding with the absorption spectrum of these two opsins 
and the blue-green light illumination regime (Table 1.1). 
 
Figure 5.9 Determination of opsin expression in murine islets. Representative agarose 
gels of RT-PCR products for one primer set for each opsin. A -RT sample was used as 
control to exclude gDNA contamination. Exposure time was automatically adjusted for each 
gel. 
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Figure 5.10 Determination of opsin expression in human islets. Representative agarose 
gels of RT-PCR products for one primer set for each opsin. A -RT sample was used as 
control for gDNA contamination. Exposure time was automatically adjusted for each gel. 
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Table 5.1 Summary of murine and human opsin expression. Band appearance, correct 
band size as well as final sequencing results for each murine and human opsin are 
displayed. 
Opsin Band Band size Sequencing result 
MURINE ISLETS 
Rhodopsin YES CORRECT RHODOPSIN 
OPN1SW (SW) NO - - 
OPN1MW 
(MW) YES CORRECT INCORRECT 
Melanopsin YES CORRECT INCORRECT 
OPN3 YES CORRECT OPN3 
OPN5 NO - - 
HUMAN ISLETS 
Rhodopsin YES CORRECT RHODOPSIN 
OPN1SW (SW) NO - - 
OPN1MW 
(MW) NO - - 
OPN1LW (LW) NO  - 
Melanopsin YES INCORRECT INCORRECT 
OPN3 YES CORRECT OPN3 
OPN5 NO - - 
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5.2.3.5 MAPK/Erk signaling activation in murine OPN3-/- islets 
To test the hypothesis that OPN3 is responsible for light-induced effects, islets from 
OPN3-/- mice were investigated. Light-induced MAPK/Erk pathway activation was 
assessed in islets from OPN3-/- mice and compared to pathway activation in islets 
from wildtype C57BL/6J by immunoblotting. Whereas all previous experiments were 
performed in islets from mice with a CD-1 genetic background, OPN3-/- had a 
C57BL/6J genetic background, therefore an additional C57BL/6J wildtype control 
was introduced to exclude any variability caused by the genetic background. Islets 
from OPN3-/- mice showed an increase in signaling, contrary to the expected 
reduced level of MAPK/Erk pathway activation compared to wildtype upon 
blue-green light illumination (Figure 5.11). This result indicated that OPN3 alone was 
not required for the light-induced effects in pancreatic islets.  
 
Figure 5.11 Involvement of OPN3 in light-based MAPK/Erk activation in pancreatic islets. (A) 
Quantification of pErk levels in murine islets from wildtype (WT) and OPN3-/- mice assessed 
by immunoblotting Mean values ± SEM are shown for three independent experiments. (B) 
Representative immunoblot of BG-light-induced pErk increase; Loading Ctr: vinculin; light 
intensity: 64 µW/cm2; duration of illumination: 5 minutes 
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5.2.3.6 Influence of blue-green light illumination on ATP levels. 
To test as an alternative mechanism, whether blue-green-light-induced effects were 
triggered by light stimulation of CcO, ATP levels in murine islets, upon blue-green 
light illumination, were determined at three different time points (2 minutes, 10 
minutes, 24 hours). There were no significant changes in ATP levels upon 
blue-green light illumination at all time points (Figure 5.1). These results suggest that 
blue-green light illumination did not act through CcO because for this an increase in 
ATP levels would be expected.  
 
Figure 5.12 Quantification of ATP levels of murine islets upon BG light illumination. 
(A) ATP levels of murine islets upon 2 minutes (2 min) of BG light illumination normalized to 
total protein concentration. All Mean values ± SEM are shown for three independent 
experiments. (B) ATP levels of murine islets upon 10 minutes (10 min) of BG light 
illumination normalized to total protein concentration. Mean values ± SEM are shown for five 
independent experiments. (C) ATP levels of murine islets upon 24 hours (24 h) of BG light 
illumination, normalized total protein concentration. Mean values ± SEM are shown for three 
independent experiments. (A-C) Light intensity: 64 µW/cm2; two-tailed, paired Student’s t–
test; a value of p ≤ 0.05 was considered to be significant (n.s.: not significant) 
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5.3 Discussion 
The second part of this thesis focused on a light-based approach for pancreatic 
β-cell expansion, without the necessity of gene transfer, through the discovery and 
characterization of endogenous light-response mechanisms. To the end, the 
influence of visible light on cell proliferation and survival in pancreatic islets was 
investigated. It was shown that blue-green light illumination leads to activation of 
proliferative and pro-survival signaling pathways and subsequently an increase in 
cell proliferation. Compared to cell lines or other primary tissues, the level of 
proliferation increase (1.6- and 1.4-fold, Figure 5.1) appears modest but is 
considerable in light of the intrinsically low turnover of β-cells. Furthermore, the 
magnitude of these effects is comparable to published data, where different growth 
factors or growth factor receptors were used to increase β-cell 
proliferation.102,176,179,180 Previous studies also have shown that a rather small 
increase in β-cell proliferation is sufficient to regulate glucose levels in diabetic 
disease models.102,179 In human islets, it was additionally demonstrated that the 
proliferative effect does not lead to dedifferentiation and subsequent decrease of 
overall β-cells mass or loss of β-cell functionality, and that illuminated islets even 
showed an increased number of proliferative β-cells compared to dark controls 
(Figure 5.2). Furthermore, a trend was observed that islets responded with an 
increased insulin secretion potential, under high glucose conditions, in response to 
light treatment. Similarly, the overall amount of internal insulin of illuminated islets 
stayed constant compared to controls, further indicating that blue-green light 
illumination had no negative effect on β-cells integrity. These findings are 
groundbreaking, as previous studies have shown that increased proliferation induced 
by growth factor administration can lead to decreased insulin levels, presumably 
because of dedifferentiation of β-cells into non-insulin producing cells.103,176 The total 
β-cells mass as well as β-cells specific proliferation was only assessed in human 
islets and not in murine islets due to their different islet composition. Murine islets 
innately exhibit a high number of β-cells, up to 80%, whereas human islets exhibit 
only around 50% β-cells. Therefore an imbalance in islets cell composition, due to 
β-cells loss is easier to detect and more relevant in human islets. 
As it was previously shown that prolonged activation of MAPK/Erk pathway is 
involved in β-cell proliferation,181 this was the first pathway that was investigated 
here. It was demonstrated that five minutes of blue-green light illumination was 
sufficient to activate MAPK/Erk pathway in murine and human islets. Moreover, 
activation of the PI3K/Akt signaling cascade, a key player in cell survival, was also 
found.181 Together, these results showed that blue-green light can activate both, 
major proliferative and pro-survival pathways in murine and human islets comparably 
to growth factors (Figure 5.4, Figure 5.5). This suggests that blue-green light 
illumination of pancreatic islets as a therapeutical approach for diabetes could have 
a double effect: first, expansion of the β-cell mass could be generated through 
inducing proliferation of existing β-cells; and second, both surviving and newly 
regenerated β-cells could have increased chances of survival.  
In order to unravel the detailed characteristics of this endogenous light-sensitive 
mechanism, the precise light requirements were determined. In particular, it was 
determined which wavelengths are able to induce pathway activation, and whether a 
light dose-response curve can be observed. In addition to blue-green light, 
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interestingly green light alone was also sufficient to activate the MAPK/Erk pathway, 
but was not enough to increase proliferation of murine islets. The mechanistic 
background of this inconsistent outcome is yet unknown. A higher sample number 
for the proliferation assay could potentially clarify this outcome, as a positive effect of 
green light on islets proliferation was possibly missed due to the small sample size in 
that particular treatment group. Blue and red light had no effect in murine islets. 
Observing a similar level of Erk phosphorylation upon white light illumination 
compared to blue-green light illumination was not surprising, as white light contains 
all wavelengths, and thus includes both, blue and green light. Blue-green light was 
further used to determine a possible light dose-response curve with regard to 
MAPK/Erk pathway activation. It was observed that there was no light intensity 
dependent phosphorylation of Erk. Every illumination protocol resulted in increased 
pErk levels, even at very low intensities, indicating that this endogenous light-
sensing mechanism is rather robust with regard to light intensities. The fact that the 
light-dependent effect is visible over a large range of intensities is a good indication 
regarding future in vivo as well as therapeutical uses, as the application of light over 
wide intensity range is sufficient to induce the positive effects and no highly precise 
light administration is necessary. The lack of a clear light dose-response curve could 
also indicate the involvement of two different light-sensing mechanisms, for example 
two different opsins, with different response curves themselves that together form a 
non-sigmoidal relationship. This hypothesis is substantiated, by the fact that non 
mammalian opsins such as JellyOp show a clear dose-response curve over the test 
intensity range.182 
Although the behavioral influence of blue-green light as well as the signaling 
pathway activation was clearly characterized in this study, there are still questions 
left unanswered. In particular, the exact mechanism of how islets cells sense light 
and the upstream mechanism of MAPK/Erk and PI3K/Akt pathway activation is still 
unclear. The observed effects were proven to be not induced by environmental 
factors such as temperature changes and are really light-induced (Figure 5.8). Based 
on previous studies45,168-171 as well as the results of opsin expression experiments 
(Table 5.1), different hypotheses were developed (Figure 5.13). The first hypothesis 
was that the non-visual opsin OPN3 plays a major role in the endogenous light-
sensing mechanism. This hypothesis was underpinned by the robust expression of 
the protein in mouse and human pancreatic islets, previously published data that 
showed OPN3-dependent Erk signaling activation and increased proliferation upon 
illumination45,168,169 as well as the consistent excitation profile of OPN3 and the used 
wavelengths (Table 1.1). By using a knockout mouse model of OPN350, the influence 
of OPN3 on the light-induced effect was investigated. The deletion of OPN3 in 
murine islets did not result in the expected decrease in light-induced MAPK/Erk 
activation compared to wild type mice; it rather led to an increase (Figure 5.11). This 
increase in signaling activation suggests that OPN3 is not required for light-
dependent effects, but may work as a light-dependent antagonist of the proliferative 
effects. Thus the knockout of OPN3 released the antagonistic break and the light-
dependent proliferative signal was increased. An observation supporting this theory 
is that in pufferfish and mosquito OPN3 was shown to couple to Gαi, which results in 
decreased cAMP levels.46 Previous studies have found that GPCRs including the 
GLP-1 receptor had a positive effect on β-cell proliferation and survival.183,184 
Notably, the GLP-1 receptor couples to Gαs, which leads to an increase in cAMP 
levels, exactly the opposite effect that results from OPN3 activation in pufferfish and 
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mosquito. However, for mammalian OPN3, G-protein coupling has not been 
identified yet. To validate this antagonistic hypothesis, further studies are needed, for 
example proliferation assays including islets of OPN3-/- mice to show that also 
proliferation and not only signaling is increased in these islets. Further, a second 
approach to knock out OPN3 in islets, such as siRNA, would be needed to verify the 
used OPN3-/- mouse model. The second hypothesis was the involvement of CcO in 
the light-sensing mechanism. Various previous studies focusing on 
photobiomodulation, also called low-level light therapy, showed that irradiation of 
different cells with light lead to an increase in ATP levels and subsequent increase in 
proliferation was mediated by the light-sensing character of CcO.171,174 Although all 
of these studies focused on red/near-infrared light illumination, this option was taken 
into consideration, as CcO has not only an absorption peak at the red/near-infrared 
range but also at around 430 nm.175 While the used activation wavelengths are not at 
the exact absorption peak, they are still in the range of CcO absorption. Different 
time intervals of illumination were tested to assess ATP levels of islets. Neither short 
term illumination, nor long term illumination led to a significant change in ATP levels 
(Figure 5.12), demonstrating that an ATP-dependent mechanism that would be 
required for the CcO hypothesis is not involved in blue-green-light-induced signaling 
activation and proliferation in islets.  
After excluding OPN3 and CcO as light-sensing actuator in pancreatic islets, the last 
remaining option is rhodopsin as actuator of the observed light-dependent effects. It 
seems that rhodopsin is expressed in lower levels compared to OPN3, but is also 
found in both mouse and human islets. The absorption maximum of rhodopsin (500 
nm) is also consistent with the wavelengths used for islet illumination (Table 1.1).51 
Light-activated rhodopsin in the rodent retina was previously found to induce 
phosphorylation of the β-subunit of the insulin receptor (IR) in the rod outer segment, 
which further leads to the activation of PI3K in an arrestin and Src dependent 
manner.185 Interestingly, it was also shown that β-arrestin underlies the proliferative 
effect of GLP-1 in pancreatic β-cells via the interaction of c-Src and the subsequent 
transactivation of the epidermal growth factor receptor.186,187 Visual arrestins 
(arrestin 1 and 4) are expressed only in rod and cone cells, β-arrestin 1 and 2 
(arrestin 2 and 3), however, are ubiquitously expressed in mammalian tissue.188 
While arrestins were originally discovered to be responsible for receptor 
desensitization, they are now also characterized as an adapter molecule to initiate 
various signaling cascades such as the MAPK/Erk, JNK, and p38 pathway as well as 
the transactivation of other receptors.185,186,189,190 These findings strengthen the 
suspicion that rhodopsin may be the trigger of light-induced proliferation in 
pancreatic islets via light-dependent coupling to arrestin and subsequent activation 
of the MAPK/Erk and PI3K/Akt pathway. This hypothesis can be proven by using a 
rhodopsin knockout mouse model to investigate the influence of rhodopsin on 
light-dependent signaling and proliferative effects. Additionally, signaling molecules 
such as c-Src as well as possible transactivated receptors such as IR and epidermal 
growth factor receptor can be investigated.  
In addition to experiments focusing on the characterization of the light-sensing 
mechanism, also in vivo studies will have to be performed to prove the translational 
potential of this approach. In particular, it has to be shown that 
blue-green-light-induced β-cell expansion can permanently normalize hyperglycemia 
in diabetic animal models. Although further investigations are needed, this approach 
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has great translational capability as it does not include any gene transfer to make the 
target tissue light responsive. The required implant to enable blue-green light 
activation is almost negligible, in particular in the context that no gene therapy is 
needed, because as discussed in section 4.3, red-light-activated systems are also 
not suitable for an implant-free therapeutical approach for diabetes in humans. As 
optogenetics is maturing into a candidate for next generation therapeutics, several 
methods are currently developed to improve light delivery to tissues, such as 
wireless implants and light guiding hydrogels.103,191 In addition, non-optical devices 
for implantation at the pancreas are currently being developed,192,193 which can be 
used as a model to engineer a specific illumination device for the pancreas. In 
addition, to in vivo regeneration and expansion of β-cells, another suitable 
application of this new light-based approach is its use for ex vivo expansion of the 
β-cell mass. Ex-vivo expansion of human β-cells is considered as a promising 
approach to provide enough insulin-producing cells for β-cell replacement therapy in 
diabetes. Expansion of adult β-cells from the limited donor numbers is an attractive 
prospect. However, attempts at expanding β-cells ex vivo frequently result in 
dedifferentiation of β-cells and consequently loss of the insulin-secreting phenotype, 
raising doubts about the therapeutic potential of this approach.194 As mentioned 
above, β-cells expanded by blue-green light illumination did not dedifferentiate and 
did not lose their insulin-secreting potential, thus representing the perfect technology 
for ex vivo β-cells expansion, by overcoming the limitations of current techniques. 
This approach would not only enable the expansion of β-cells ex vivo prior to 
transplantation, thereby lowering the number of required donor tissue, but would also 
enable the increase of surviving cells after transplantation and further expansion of 
β-cells by ongoing in vivo illumination after transplantation. Summarized, after fully 
characterizing this light-based approach ex vivo and in vivo, it has a great potential 
to overcome various limitations of current methods and will be applicable in a broad 
spectrum of therapeutical approaches from ex vivo β-cells expansion to in vivo 
regeneration of the β-cell mass. 
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Figure 5.13 Summary and outlook of hypothesis for light-sensing mechanism. It was 
hypothesized that OPN3, a robustly expressed opsin, or CcO could be responsible for the 
light-induced proliferative effect in pancreatic islets. These hypotheses were disproved by an 
OPN3 knockout mouse model (OPN3 KO) and an assay that determined ATP levels after 
illumination. Another possible mechanism is the involvement of rhodopsin, which has to be 
verified by a rhodopsin knockout (Rho KO) mouse model. 
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CHAPTER 6: CONCLUDING REMARKS AND FUTURE 
DIRECTIONS  
The development of red-light-activated RTKs opens a new avenue for optogenetics 
research by allowing non-invasive activation of RTKs in vivo, in particular as red light 
offers deeper tissue penetration than other wavelengths in the visible spectrum. This 
strengthens the argument that red-light-activated RTKs can be the ideal tool for 
many in vivo studies, ranging from spatial and temporal analysis of growth factor 
involvement in degenerative diseases to developmental and behavioral studies. In 
addition to deep tissue penetration, red light has a further major advantage 
compared to other wavelengths in the visible spectrum: it does not overlap with the 
excitation wavelength of commonly used fluorescent probes, and consequently this 
feature allows the use of red-light-activated RTKs for multi-color cell signaling 
experiments in an all-optical manner. A blueprint of such a multi-color cell signaling 
experiment is illustrated in Figure 6.1 A and B, where two different fluorescent 
reporters were used to determine MAPK/Erk activation (SRE-mCherry) and cell 
viability (CMV-mCer3) simultaneously. These reporters, combined with 
red-light-activated RTKs, allow to determine the influence of different small 
molecules on signaling activation and cell viability in parallel and an all-optical 
manner. This multi-color cell signaling approach can, in the future, be combined with 
the previously published approach of an all-optical drug screen,195 leading to 
improvement and expansion of applicability and validity of the screening platform. 
The combination of red-light-activated RTKs with different fluorescent signaling 
reporters would, for example, enable the screening of small molecules acting on 
different pathways simultaneously in an unprecedented, rapid and economic way. 
 
Figure 6.1 Multicolor cell signaling experiment tested receptor/pathway inhibition and 
cell viability simultaneously in an all optical manner. (A) I) CMV–mCerulean3 is 
expressed constitutively and acts as viability reporter, whereas SRE–mCherry depends on 
activation of the MAPK/Erk pathway by light-activated RTKs (mCer3: mCerulean3). II) The 
addition of a toxin such as DMSO leads to cell death, thereby resulting in expression of 
neither mCherry nor mCer3. III) The addition of a specific MAPK/Erk pathway inhibitor such 
Trametinib (TRA) inhibits mCherry expression, whereas viability and therefore mCer3 
expression is not affected. (B) Experimental realization of (A). Activation of the MAPK/Erk 
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pathway in response to red light (R), of untreated cells, DMSO treated cells or TRA (0.1 µM) 
treated cells. Pathway activation and cell viability is expressed as relative fluorescence units 
(RFU) of mCherry and mCer3, respectively. Mean values ± SEM for three independent 
experiments, each performed in triplicate, are shown. Light intensity: 6.2 µW/cm2; duration of 
illumination: 18 hours 
Another innovative light-based approach is the activation of endogenous light-
responsive mechanisms to expand pancreatic islets. As discussed in section 5.3, 
further studies are essential in order to characterize the light based mechanism in 
detail, and in vivo studies are required to provide insight into the translational 
potential. Nevertheless, this approach promises great potential for future therapies, 
as it includes all advantages of common optogenetic approaches, such as temporal 
and local precision, but additionally, it does not require gene transfer to make tissues 
light responsive. Gene transfer is a requirement of common optogenetic tools, 
limiting their use as therapeutics in a broad spectrum, as gene therapy comes with 
many risk factors and is therefore still not used widely. Because this new approach is 
based only on the local delivery of visible light to the pancreas and relies solely on 
endogenous responses to light, it could be the basis for future diabetic therapy 
without further risks and side effects. Moreover, the light-based expansion of cells is 
not limited to pancreatic islets,168 and further investigations can identify other tissue 
types all over the body which are responsive to visible light. Interestingly, in 
preliminary cell line based experiments (Figure 6.2) it was shown that not only 
pancreatic cells (INS-1E and primary islets cells) are light responsive, but also other 
cell lines such as HEK293 cells. In particular, the responsiveness to light of three 
different cell lines was tested. Two different signaling cascades were investigated, a 
cAMP-based cascade and the MAPK/Erk pathway, as well as changes in cell 
viability upon illumination (Figure 6.2, Figure A1, Figure A2, Figure A3). The results 
showed that different cell lines were responsive to visible light in different ways. 
Considering these results, it is worth to further investigate various tissues for their 
light responsiveness in order to expand the approach of light-induced proliferation by 
endogenous mechanisms, and to find new therapeutical approaches for various 
degenerative diseases.  
 
Figure 6.2 Influence of visible light on cellular signaling and cell behavior in different 
cell lines. Results are displayed as color code translated from fold induction compared to 
dark controls. Each result indicates the quantification of three independent experiments. 
HEK293 cells show an increase in pErk levels as well as cAMP levels after illumination. 
HeLa cells show only a minimal increase in cAMP levels upon illumination. INS-1E cells 
show increase in pErk levels, increased viability as well as small increased cAMP levels 
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upon illumination with visible light. Detailed experimental outcomes are depicted in Figure 
A1, Figure A2 and Figure A3. 
To conclude, in this study two different light-based approaches were established and 
investigated in order to overcome limitations of common optogenetic and 
pharmacological methods, such as local and temporal precision as well as tissue 
penetration, and gene delivery. These new approaches are important tools which 
can be used in basic research as well as for the invention of new therapies for 
degenerative diseases such as diabetes. 
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APPENDIX 
Table A1 Oligonucleotides for genotyping of OPN3-/- mice. 
Number Name Sequence 
1 OPN3WT_F TGTACCGTGGACTGGAGATCCAAG 
2 OPN3-/-_F TTATGGCCCACACCAGTGGC 
3 FOPN3_R GTTCCCACA CACGACCTGCTC 
Table A2 Oligonucleotides utilized in genetic engineering. Restriction sites are 
underlined. 
Number Name Sequence 
1 CPH1S_XmaI_F GCTACCCGGGGCCACCACCGTACAACTCAG 
2 CPH1S_XmaI_R GCTACCCGGGTTCTTCTGCCTGGCGCAAAAT
 3 CPH1So_XmaI_F GATCCCCGGGGCAACTACTGTTCAACTGTCT
 4 CPH1So_XmaI_R GATCCCCGGGTTCTTCAGCTTGGCGCAGAAT
 5 truncated 
 
TGGGAGGTCTATATAAGCAGAGC 
6 truncated 
 
GGCGGGCCATTTACCGTAAG 
7 mF_inverse_SgrAI_F GATCCACCGGTGGAGCAACTACTGTTCAACT
 8 mF_ inverse_SgrAI_R GATCCACCGGTGACGTCGAGGCGCTG 
9 rtrkB_BspEI_F GATCTCCGGAAAGTTTGGCATGAAAG 
10 rtrkB_AgeI_R CAGAAACCGGTGCCTAGGATGTCCAG 
11 mF_YY271/2FF_F GAGACATTCATCATATCGACTTCTTCAAGAAA
 12 mF_YY271/2FF_R GGCCGTTGGTGGTTTTCTTGAAGAAGTCGAT
 13 mF_R195E_F TACAGGCCCGGGAGCCTCCTGGGCTGGAGT
 14 mF_R195E_R TTATAGCAGTACTCCAGCCCAGGAGGCTCCC
 15 TrkB-CP1 K131A F TGGCCGTGGCGACGCTGAAGGAC 
 16 TrkB-CP1 K131A R GTCCTTCAGCGTCGCCACGGCCA 
 17 pGL4_inverse_AscI_F GATCATGGCGCGCCCTAAGGCCGCGACTCTA
 18 pGL4_inverse_ AscI_R ATGATCGGCGCGCCGGTGGCTTTACCAACAG
 19 mCherry_AscI_F CATCAGGCGCGCCATGGTGAGCAAGGGCGA
 20 mCherry_AscI_R GATCAGGCGCGCCTTACTTGTACAGCTCGTC
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Table A3 Oligonucleotides utilized for RT-PCR to determine opsin expression in 
mouse, humane islets. 
Number Name Sequence 
1 m-bActin _F CCTGAACCCTAAGGCCAACC 
2 m-bActin _R CTCGTAGATGGGCACAGTGTG 
3 mInsulin _F GCGTGGCTTCTTCTACACAC 
4 mInsulin _R GTTCTCCAGCTGGTAGAGGG 
5 mOPN1SW _F1 GTCATCTGTAAACCCTTCGGC 
6 mOPN1SW _R1 GTACTCGCTTCGATACTTGGTG 
7 
 
mOPN1SW _F2 CTGCTACGTGCCCTATGCTG 
 8 
 
mOPN1SW _R2 GATGGTGACAAGCCGTAAGTCC 
9 mOPN1MW _F1 GCAGTTGCTGACCTAGCAGAG 
10 mOPN1MW _R1 CTTGCAGACCACCAGCCATC 
11 mOPN1MW _F2 GCCCTTTGGCAATGTGAGAT 
12 mOPN1MW _R2 CCAGACCCAGGAGAAGACGAT 
13 mOPN3 _F1 CCATTACCACCCTCACTGTGC 
14 mOPN3 _R1 CAGCCCAGTCCATGTATGTC 
15 mOPN3 _F2 GATGGCCTTTGTCTTTCTCACC 
16 mOPN3 _R2 GGTGTCCATAGCCATTGACCA 
17 mMelanopsin _F1 CTCTTTGGGGAGACAGGTTG 
18 mMelanopsin _R1 CAGGGCATAAAGCCAGACGCC 
19 mMelanopsin _F2 GATACTCGCACATCCTGACGC 
20 mMelanopsin _R2 AATGGGATTGTGGATGGCAG 
21 mOPN5 _F1 CCATACAGCTCTCCGTGGTG 
 22 mOPN5 _R1 GATGGATCTCCAGCACAGCAG 
 23 mOPN5 _F2 CCATGTACTTGAGGTGAAGCTG 
24 mOPN5 _R2 GCTGATTTTGCAAGGAGTGTGG 
25 mRhodopsin _F1 CCTTAGGACTGAGAAAGCATCGAG 
26 mRhodopsin _R1 GCTGAGAGACATGAGGCAAGGT 
27 mRhodopsin _F2 CCACCCTCTACACATCACTCC 
28 mRhodopsin _R2 GAAGACCACACCCATGATAGC 
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29 h_b-actin _F CCACACCTTCTACAATGAGCTG 
30 h_b-actin _R CCTGGATAGCAACGTACATGG 
31 hInsulin _F GATCACTGTCCTTCTGCCATG 
32 hInsulin_R GTTCCCCGCACACTAGGTAG 
33 hOPN1SW _F1 GACTTACGGCTTGTCACCATTC 
34 hOPN1SW_R1 GGGTAGACGAGACAGTAGAAAC 
35 hOPN1SW _F2 CTTCCTGGCCTTTGAGCGC 
36 hOPN1SW_R2 GCAGAAGATGAAGAGGAACCAC 
37 hOPN1MW _F CACCTACACCAACAGCAACTC 
38 hOPN1MW _R GTTCACCAGGATCCAGTTCAG 
39 hOPN1MW _F CCACGGCCTGAAGACTTCATG 
40 hOPN1MW _R CAGGACCATCACCACCACC 
41 hOPN1LW_ F CACCTACACCAACAGCAACTC 
42 hOPN1LW _R GTTCACCAGGATCCAGTTCAG 
43 hOPN1LW_ F CTGGGAGAGATGGATGGTGG 
45 hOPN1LW _R GGTACGAGCTGCCGCTGAA 
46 hOPN3 _F CGTACCTCTTTGCTAAATCGAAC 
47 hOPN3 _R CCTGTCCCCATCTTTCTGTG 
48 hOPN3 _F CTCACCTCCTCCTGGTCAAC 
 49 hOPN3 _R CTACAAAGGACGAACTTGGATTACATC 
 50 hMelanopsin _F GACACGAAGCAGAGACTCCAG 
51 hMelanopsin _R CTCACAGCATAATCCTGGGTC 
52 hMelanopsin _F CGAGGGGTTGCTGACATCC 
53 hMelanopsin _R CTTGCACTCGCTCTGCAGCC 
54 hOPN5 _F CTGTGATCGTGTTCTCCTACG 
55 hOPN5 _R CCTTCCAAAAGCTGACCACAC 
56 hOPN5 _F GACTATCAATTTAGCAGTCTGTGATC 
57 hOPN5 _R GATCCAGGCTGACAGCAGTC 
58 hRhodopsin_F CTCAACTACATCCTGCTCAACC 
59 hRhodopsin _R CAAGGACCACAGGGCAATTTC 
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60 hRhodopsin_F CAAGCCGGAGGTCAACAACG 
 61 hRhodopsin _R GCCACGCTGGCGTAGGG 
 Table A4 Donor details 
Donor number Gender Age Weight (kg) BMI Purity 
1 Male 47 95.3 31.0 85% 
2 Female 44 106.0 34.5 90% 
3 Male 59 94.8 26.8 85% 
4 Male 34 181.0 49.9 95% 
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Figure A1 Light-dependent MAPK/Erk pathway activation in different cell lines (A) 
Representative immunoblot of blue-light-induced pErk increase in HEK293 cells. Loading 
Ctr: calnexin. (B) Representative immunoblot of blue-light-induced pErk increase in HeLa 
cells. Loading Ctr: calnexin. (C) Representative immunoblot of blue-light-induced pErk 
increase in INS-1E cells. Loading Ctr: total Akt. (D) Quantification of blue-light-induced pErk 
increase for each cell line, normalized to dark control. Mean ± SEM are shown for three 
independent experiments for each cell line. (A-D) Light intensity: 255 µW/cm2; duration of 
illumination: 5 minutes 
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Figure A2 Light-dependent variations in cell viability of different cell lines. Cell viability 
was assessed by a MTT assay. Cell viability is expressed as absorbance (Abs.) at 570 nm 
subtracted by the background (Abs. 690 nm). (A) HEK293 cells showed no significant 
change in cell viability after blue light illumination with an intensity of 64 µW/cm2. (B) HeLa 
cells showed a decreasing trend in cell viability after blue light illumination with an intensity of 
64 µW/cm2. (C) INS-1E cells showed a significant increase in cell viability after blue light 
illumination with an intensity of 255 µW/cm2. (A-C) Mean ± SEM are shown for three to 
seventeen independent experiments for each cell line. A value of p ≤ 0.05 was considered to 
be significant. Duration of illumination: 24 hours 
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Figure A3 Light-dependent cAMP level changes in different cell lines. cAMP levels are 
expressed as RLU. Results are normalized to dark values. (A) HEK293 cells showed an 
increase in cAMP levels after blue light illumination. (B) HeLa cells showed a small increase 
in cAMP levels after blue light illumination. (C) INS-1E cells showed a small increase in 
cAMP levels after blue light illumination. (A-C) Mean ± SEM are shown for three independent 
experiments for each cell line. Light intensity: 9.6 mW/cm2; duration of illumination: 3 
seconds 
 
 
